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A B S T R A C T
Background
Endoscopic therapy reduces the rebleeding rate and the need for surgery in patients with bleeding peptic ulcers.
Objectives
To determine whether a second procedure improves haemostatic efficacy or patient outcomes or both after epinephrine injection in
adults with high-risk bleeding ulcers.
Search methods
For our update in 2014, we searched the following versions of these databases, limited from June 2009 toMay 2014:OvidMEDLINE(R)
1946 to May Week 2 2014; Ovid MEDLINE(R) Daily Update May 22, 2014; Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations May 22, 2014 (Appendix 1); Evidence-Based Medicine (EBM) Reviews-the Cochrane Central Register of Controlled Trials
(CENTRAL) April 2014 (Appendix 2); and EMBASE 1980 to Week 20 2014 (Appendix 3).
Selection criteria
We included randomised controlled trials (RCTs) comparing epinephrine alone versus epinephrine plus a second method. Populations
consisted of patients with high-risk bleeding peptic ulcers, that is, patients with haemorrhage from peptic ulcer disease (gastric or
duodenal) with major stigmata of bleeding as defined by Forrest classification Ia (spurting haemorrhage), Ib (oozing haemorrhage), IIa
(non-bleeding visible vessel) and IIb (adherent clot) (Forrest Ia-Ib-IIa-IIb).
Data collection and analysis
We used standard methodological procedures as expected by The Cochrane Collaboration. Meta-analysis was undertaken using a
random-effects model; risk ratios (RRs) with 95% confidence intervals (CIs) are presented for dichotomous data.
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Main results
Nineteen studies of 2033 initially randomly assigned participants were included, of which 11 used a second injected agent, five used a
mechanical method (haemoclips) and three employed thermal methods.
The risk of further bleeding after initial haemostasis was lower in the combination therapy groups than in the epinephrine alone group,
regardless of which second procedure was applied (RR 0.53, 95% CI 0.35 to 0.81). Adding any second procedure significantly reduced
the overall bleeding rate (persistent and recurrent bleeding) (RR 0.57, 95% CI 0.43 to 0.76) and the need for emergency surgery (RR
0.68, 95% CI 0.50 to 0.93). Mortality rates were not significantly different when either method was applied.
Rebleeding in the 10 studies that scheduled a reendoscopy showed no difference between epinephrine and combined therapy; without
second-look endoscopy, a statistically significant difference was observed between epinephrine and epinephrine and any second endo-
scopic method, with fewer participants rebleeding in the combined therapy group (nine studies) (RR 0.32, 95% CI 0.21 to 0.48).
For ulcers of the Forrest Ia or Ib type (oozing or spurting), the addition of a second therapy significantly reduced the rebleeding rate (RR
0.66, 95% CI 0.49 to 0.88); this difference was not seen for type IIa (visible vessel) or type IIb (adherent clot) ulcers. Few procedure-
related adverse effects were reported, and this finding was not statistically significantly different between groups. Few adverse events
occurred, and no statistically significant difference was noted between groups.
The addition of a second injected method reduced recurrent and persistent rebleeding rates and surgery rates in the combination
therapy group, but these findings were not statistically significantly different. Significantly fewer participants died in the combined
therapy group (RR 0.50, 95% CI 0.25 to 1.00).
Epinephrine and a second mechanical method decreased recurrent and persistent bleeding (RR 0.31, 95% CI 0.18 to 0.54) and the
need for emergency surgery (RR 0.20, 95% CI 0.06 to 0.62) but did not affect mortality rates.
Epinephrine plus thermal methods decreased the rebleeding rate (RR 0.49, 95% CI 0.30 to 0.78) and the surgery rate (RR 0.20, 95%
CI 0.06 to 0.62) but did not affect the mortality rate.
Our risk of bias estimates show that risk of bias was low, as, although the type of study did not allow a double-blind trial, rebleeding,
surgery and mortality were not dependent on subjective observation. Although some studies had limitations in their design or imple-
mentation, most were clear about important quality criteria, including randomisation and allocation concealment, sequence generation
and blinding.
Authors’ conclusions
Additional endoscopic treatment after epinephrine injection reduces further bleeding and the need for surgery in patients with high-
risk bleeding peptic ulcer. The main adverse events include risk of perforation and gastric wall necrosis, the rates of which were low
in our included studies and favoured neither epinephrine therapy nor combination therapy. The main conclusion is that combined
therapy seems to work better than epinephrine alone. However, we cannot conclude that a particular form of treatment is equal or
superior to another.
P L A I N L A N G U A G E S U M M A R Y
Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Background
Peptic ulcers develop when the usual protective mechanism of the body breaks down and digestive juices produced in the stomach,
intestines and digestive glands damage the lining of the stomach or duodenum. Non-steroidal anti-inflammatory drugs and a bacterium
called Helicobacter pylori are common causes of ulcers.
When ulcers in the stomach and small intestine (duodenum) start to bleed extensively (haemorrhage), the bleeding can be life threatening
and requires emergency treatment.
Patients undergo an endoscopy so clinicians can locate the source of bleeding. Active bleeding or non-bleeding visible blood vessels
at endoscopy are deemed ’high risk,’ in that further bleeding may occur even if the initial haemorrhage can be stopped. Once the
source of bleeding has been identified, endoscopic therapy reduces rebleeding rate, need for surgery and deaths. Endoscopic therapy
consists of an agent to stop the bleeding, which is injected into the bleeding area; epinephrine (adrenaline) is the most popular agent.
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Experts disagree on the need for a second procedure such as bipolar electrocoagulation, heater probe, sclerosant or clips immediately
after epinephrine; although it seems to reduce further bleeding, the effects of a second procedure on continuing illness (morbidity),
surgery rates and death remain unclear.
Review question
In bleeding peptic ulcers, does a second endoscopic method reduce further bleeding, the need for emergency surgery and death rates?
Study characteristics
We performed an extensive search for randomised trials comparing epinephrine alone versus epinephrine plus a second method. We
found 19 clinical trials involving 2033 randomly assigned participants
Key results
We found that adding a second procedure reduced the further bleeding rate and the need for emergency surgery, but the effect of
this approach on death rates has not been proven. In conclusion, additional endoscopic treatment after epinephrine injection reduces
further bleeding and the need for surgery in patients with high-risk bleeding peptic ulcer.
Quality of the evidence
Our risk of bias estimates show that the overall quality of the included studies was moderate or high. Although some studies had
limitations in their design or implementation, most were clear about important quality criteria including randomisation and allocation
concealment, sequence generation and blinding. We rated the quality of evidence as moderate for most outcomes. Further research is
likely to have an impact on our confidence in the estimate of effect and may change the conclusions of this review.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Epinephrine versus epinephrine and any second endoscopic method in high-risk bleeding ulcers
Patient or population: patients with high-risk bleeding ulcers
Settings: secondary care (hospital)
Intervention: epinephrine versus epinephrine and any second endoscopic method
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Epinephrine
versus epinephrine and
any second endoscopic
method
Recurrent and persistent
bleeding overall rates
with or without second-
look endoscopy
Rebleeding (persistent or
recurrent bleeding)
Study population RR 0.57
(0.43-0.76)
1926
(19 studies)
⊕⊕⊕©
moderatea
Favours combined ther-
apy
223 per 1000 127 per 1000
(96-170)
Moderate
222 per 1000 127 per 1000
(95-169)
Surgery rate
Number requiring emer-
gency surgery
Study population RR 0.68
(0.5-0.93)
1841
(18 studies)
⊕⊕⊕©
moderateb
Favours combined ther-
apy
106 per 1000 72 per 1000
(53-99)
Moderate
102 per 1000 69 per 1000
(51-95)
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Mortality rate
Number of deaths (30-
day mortality or in-hospi-
tal mortality)
Study population RR 0.64
(0.39-1.06)
1841
(18 studies)
⊕⊕⊕©
moderateb
Favours combined ther-
apy
47 per 1000 30 per 1000
(18-49)
Moderate
32 per 1000 20 per 1000
(12-34)
Adverse effects of en-
doscopy therapy
Adverse effects
Study population RR 1.25
(0.4-3.96)
1281
(12 studies)
⊕⊕⊕©
moderateb
No statistically signifi-
cant difference between
groups8 per 1000 10 per 1000
(3-31)
Moderate
0 per 1000 0 per 1000
(0-0)
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aModerate statistical heterogeneity was present.
bRelatively few events.
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B A C K G R O U N D
Description of the condition
Peptic ulcers develop when the usual protective mechanism of the
body breaks down and digestive juices produced in the stomach,
intestines and digestive glands damage the lining of the stomach
or duodenum. Non-steroidal anti-inflammatory drugs and Heli-
cobacter pylori are the most common causes of peptic ulcer.
Bleeding peptic ulcer is a serious condition in which ulcers in the
upper digestive system (stomach) and the small intestine (duode-
num) start to bleed extensively (haemorrhage). The bleeding can
be life threatening and requires emergency treatment.
Patients usually require an endoscopy during the first 24hours after
admission so clinicians can locate the source of bleeding (Cooper
1999). Patients with active bleeding or non-bleeding visible vessels
at endoscopy are deemed ’high risk,’ as this finding predicts risk
of further bleeding and guides management decisions. Once the
source of bleeding has been identified, endoscopic therapy reduces
rebleeding rate, need for surgery and morbidity and mortality
among patients bleeding from a peptic ulcer (Cook 1992).
Endoscopic therapy should be provided to patients with stigmata
of high risk (Laine 2012). Such high-risk patients receive endo-
scopic therapy consisting of an agent to stop the bleeding, which
is injected into the bleeding area. Injection of epinephrine is the
most popular method used to stop bleeding. Second endoscopic
methods may include bipolar electrocoagulation, heater probe,
sclerosant or clips. At the time of publication of the first version of
this review, some experts disagreed on the need for a second pro-
cedure immediately after epinephrine; although it seems to reduce
further bleeding, the effects of a second procedure on continuing
illness (morbidity), surgery rates and death (mortality) remain un-
clear.
Description of the intervention
Many different endoscopic haemostatic techniques have been de-
veloped and studied over the past 25 years. Methods are based
on injection of vasoconstrictor substances (epinephrine), scle-
rosant substances (polidocanol, absolute alcohol), clotting factors
(thrombin, fibrin glue) or adhesives (cyanoacrylate). Thermal ther-
apies include laser, monopolar electrocoagulation, argon plasma
coagulation, bipolar probes and heater probe. More recently, use
of mechanical devices to clip the bleeding vessel (haemoclip) has
been incorporated. Epinephrine injection-alone or in combina-
tion with another technique-has become the most popular endo-
scopic method for emergency endoscopic haemostasis because of
its safety, low cost and easy application (Savides 2000).
Previous guidelines suggested that no clear evidence shows that
any technique is superior to injection of epinephrine alone for the
endoscopic treatment of high-risk bleeding peptic ulcers (British
Society 2002; Feu 2003; Laine 2009). However, some individ-
ual studies have reported a significant reduction in further bleed-
ing rates with the addition of a second endoscopic treatment
(Chung 1997; Garrido 2002; Kubba 1996; Lin 1999; Lo 2006).
Although absolute improvements in haemostatic efficacy were rel-
atively small (from 10% to 20%), they represent a 30% to 60%
reduction in the relative risk of recurrent haemorrhage.
At the time of publication of the first version of this review, al-
though some randomised studies had established that epinephrine
in combination with a second haemostatic technique is better
than epinephrine alone, guidelines available at the time did not
provide clear recommendations on this point (British Society
2002; Feu 2003). The American Society for Gastrointestinal En-
doscopy (ASGE) suggests that combination therapy is better than
epinephrine alone for the treatment of peptic ulcer bleeding
(ASGE 2004). After publication of the first version of our review
in The Cochrane Library (Vergara 2007), further reviews recom-
mended combined treatment for high-risk peptic ulcer (Kovacs
2008; Peter 2008). Since then, updated guidelines for acute non-
variceal bleeding have been produced. The ASGE has recom-
mended that if “epinephrine is used to treat peptic ulcer bleeding
with high-risk stigmata, a second endoscopic treatment modal-
ity (co-aptive thermal device, sclerosants, thrombin/fibrin glue or
clips) should also be used” (Hwang 2012). This is also stated in
UK National Institute for Health and Care Excellence (NICE)
guideline, which indicates that epinephrine should not be used
alone for the treatment of bleeding, but it should be used in com-
bination with a mechanical method, thermal coagulation or fibrin
or thrombin (NICE 2012). Repeat endoscopy, with treatment as
appropriate, should be considered for all patients at high risk of
rebleeding, particularly if doubt exists about adequate haemostasis
at the first endoscopy. The American College of Gastroenterol-
ogy (AGA) Guideline of 2012 (Laine 2012) suggested that pa-
tients with acute upper gastrointestinal bleeding should undergo
endoscopy within 24 hours of admission, with stigmata of recent
haemorrhage recorded, as they predict risk of further bleeding (us-
ing the Forrest classification). Endoscopic therapy should be pro-
vided to patients with active spurting or oozing bleeding and to
those with a non-bleeding visible vessel. A strong recommenda-
tion with high-quality evidence suggests that epinephrine ther-
apy should be used in combination, as epinephrine monotherapy
is less effective than other monotherapies in preventing further
bleeding. The second treatments recommended include thermal
therapy and injection of a sclerosant. Clips were recommended, as
they appear to decrease further bleeding and the need for surgery,
although the guidance does state that “comparisons of clips versus
other therapies yield variable results and currently used clips have
not been well studied.” The guidance goes further and states that
“for the subset of patients with actively bleeding ulcers, thermal
therapy or epinephrine plus a second modality may be preferred
over clips or sclerosant alone to achieve initial haemostasis.” Rou-
tine second-look endoscopy was not recommended in this guide-
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line.
Why it is important to do this review
Although use of a second endoscopic procedure for the treatment
of high-risk bleeding peptic ulcers is now accepted, the addition
of a second endoscopic technique can increase cost and risk of
complications of the procedure; therefore we investigated whether
a reduction in further bleeding actually offsets these drawbacks.
In this updated review, we wanted to ensure that we included
all recently published studies of epinephrine injection versus
epinephrine and a second endoscopic method for treatment of
high-risk bleeding ulcers.
O B J E C T I V E S
To determine whether a second procedure improves haemostatic
efficacy or patient outcomes or both after epinephrine injection
in adults with high-risk bleeding ulcers.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised trials.
Types of participants
Patients with high-risk bleeding peptic ulcers, that is, patients with
haemorrhage from peptic ulcer disease (gastric or duodenal) with
major stigmata of bleeding as defined by Forrest classification:
Ia (spurting haemorrhage), Ib (oozing haemorrhage), IIa (non-
bleeding visible vessel) and IIb (adherent clot) (Forrest Ia-Ib-IIa-
IIb) (Forrest 1974).
Types of interventions
Epinephrine injection versus epinephrine injection and a second
endoscopic method.
Types of outcome measures
Primary outcomes
Rebleeding rates (persistent bleeding and recurrent bleeding) as
confirmed by endoscopy and further clinically significant bleeding
as defined according to the criteria established in each study.
Secondary outcomes
• Surgery rate.
• Mortality rate.
• Adverse effects.
Search methods for identification of studies
Electronic searches
For the first published version of this review, we searched the fol-
lowing databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (which includes the Cochrane Upper
Gastrointestinal and Pancreatic Diseases Group (UGPD) Trials
Register) (2006, Issue 1).
• MEDLINE (1966 to February 2006).
• EMBASE (1980 to February 2006).
We also searched the reference lists of articles.
We contacted experts in the field.
We searched the following databases in 2009.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (which includes the Cochrane UGPD Group
Trials Register) (2009, Issue 1).
• MEDLINE (2006 to September 2009).
• EMBASE (2006 to September 2009).
For our update in 2014, we searched the following versions of the
databases, limited from June 2009 to May 2014.
• Ovid MEDLINE(R) 1946 to May Week 2 2014 (Appendix
1).
• Ovid MEDLINE(R) Daily Update May 22, 2014.
• Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations May 22, 2014.
• EBM Reviews-Cochrane Central Register of Controlled
Trials April 2014 (Appendix 2).
• EMBASE 1980 to Week 20 2014 (Appendix 3).
The search strategy for this review was constructed by using a
combination of medical subject headings (MeSH) and text words
related to the use of epinephrine injection alone and epinephrine
injection with a secondary endoscopic therapy for the treatment
of bleeding peptic ulcers. Articles published in any language were
included.
To identify RCTs, the search strategy in Appendix 1 (MEDLINE)
was combined with recommendations provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2008).
Searching other resources
We handsearched reference lists from trials selected by electronic
searching to identify further relevant trials and published abstracts
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from conference proceedings from United European Gastroen-
terology Week (published in Gut) and Digestive Disease Week
(published in Gastroenterology).
We also contacted members of the Cochrane UGPD Group and
experts in the field to provide details of outstanding clinical trials
and relevant unpublished materials.
Data collection and analysis
Selection of studies
Two review authors separately evaluated potentially included stud-
ies, that is, studies designed to compare the efficacy of different
endoscopic methods to achieve definitive haemostasis in patients
with peptic ulcer.
Data extraction and management
Two review authors (XC and MV) extracted data, which were re-
viewed by a third review author (JPG). When results were discor-
dant, papers were jointly reviewed until differences were resolved.
For this update, CB and MV reviewed updated search results, se-
lected new trials for inclusion, extracted data separately and con-
ferred over discrepancies until consensus was achieved. CB and
MV updated the text of the review.
Assessment of risk of bias in included studies
In this updated version of the review, we introduced the risk of
bias table to assess study quality. Consistent with the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
this version of the review incorporates additional elements into
’Risk of bias’ tables that were not included in the previous pub-
lished review. Two review authors (MV with XC, MV with CB)
independently assessed study quality. Discrepancies in interpreta-
tion were resolved by consensus.
Measures of treatment effect
Risk ratios (RRs) and 95% confidence intervals (CIs) were used
in comparisons. We used a random-effects model for analyses. We
performed subanalysis for further bleeding to examine the efficacy
of different techniques (sclerosant agents, mechanical haemostasis
and thermal devices) associated with epinephrine injection versus
epinephrine alone.
Unit of analysis issues
Randomisation of clusters can result in overestimation of the pre-
cision of results (with higher risk of a Type I error) when their use
has not been compensated for in the analysis. None of the included
studies employed cluster randomisation. For studies that included
more than one active intervention group and only one control
group, we selected the interventions that most closely matched
our inclusion criteria and excluded the others (Chapter 16.5.4,
Higgins 2011).
Dealing with missing data
When data were not available in published trial reports, or when
clarification was needed, we contacted trial investigators to request
missing information.
Assessment of heterogeneity
The extent to which variations were noted in methods, popula-
tions, interventions or outcomes was assessed. Consistency of re-
sults was assessed by visual inspection of the forest plot and by
examination of I2 (Higgins 2002), a quantity that describes the
approximate proportion of variation in point estimates that is due
to heterogeneity rather than to sampling error.
Some clinical heterogeneity was noted across the included studies
(see Description of studies), as was some statistical heterogeneity
for outcomes for which it was possible to combine study data.
Quantitative syntheses of the data therefore were undertaken using
a random-effects model.
Data synthesis
Main comparisons contrasted epinephrine injection versus
epinephrine injection plus another haemostatic method. The pri-
mary outcome variable was further bleeding, defined as persistence
or recurrence of bleeding during follow-up. We analysed emer-
gency surgery during hospitalisation and morbidity and mortality
rates. All results were obtained using Review Manager 5 (RevMan
2014). The statistical tests and formulae implemented in RevMan
are described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
Subanalysis was also performed according to the type of peptic
ulcer haemorrhage observed: active spurting or oozing (Forrest Ia
or Ib), non-bleeding visible vessel (Forrest IIa) or adherent clot
(Forrest IIb). We split further bleeding rates into failure to achieve
initial haemostasis and recurrence during follow-up and analysed
the data separately. Finally, to ascertain the influence of second-
look endoscopy on the results, we analysed separately studies that
performed this procedure. We also conducted separate analyses
depending on the second type of endoscopic technique associated
with epinephrine (thermal, sclerosant or mechanical).
R E S U L T S
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Description of studies
Results of the search
Previous searches in 2006 and 2009 identified 18 included studies
and 13 excluded studies.The updated search in May 2014 identi-
fied 116 new citations (MEDLINE 45, EMBASE 83, CENTRAL
19); eight potentially relevant records were obtained and scruti-
nised; seven of these reports did not meet the inclusion criteria
(see Characteristics of excluded studies) and had to be excluded.
One new trial met the inclusion criteria and was included (Figure
1). Review authors identified a total of 19 included studies and 20
excluded studies.
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Figure 1. Study flow diagram.
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Included studies
For this update, we included one new study (Grgov 2012). Nine-
teen articles compared epinephrine injection versus epinephrine
plus any other endoscopic method for the endoscopic treatment of
bleeding peptic ulcers (Balanzo 1990; Lo 2006; Choudari 1994;
Chung 1993; Chung 1996; Chung 1997; Chung 1999; Garrido
2002; Grgov 2012; Kubba 1996; Lee 1997; Lin 1993; Lin 1999;
Loizou 1991; Park 2004; Pescatore 2002; Sollano1991;Villanueva
1993; Villanueva 1996). A total of 2033 initially randomly as-
signed participants were included. Grgov 2012 was published in
Serbo-Croatian, and Garrido 2002 in Spanish. Two studies were
published as abstracts only (Lee 1997; Villanueva 1996).
Design
All included studies were RCTs, as specified in our inclusion cri-
teria. Two studies were published as abstracts (not as papers). Six-
teen studies used a two-arm trial design (Balanzo 1990; Lo 2006;
Choudari 1994;Chung 1993;Chung 1996;Chung1997;Garrido
2002; Grgov 2012; Kubba 1996; Lee 1997; Lin 1993; Loizou
1991; Park 2004; Pescatore 2002; Villanueva 1993; Villanueva
1996); only three studies (Chung 1999; Lin 1999; Sollano 1991)
used a three-arm trial design.
Participants
Characteristics of the participants in each study were recorded,
including numbers of participants, age and gender of participants,
percentage of duodenal and gastric ulcers and Forrest type.
The number randomly assigned varied from 276 participants in
Chung 1997 to 42 participants in Loizou 1991 (the smallest trial).
Eleven studies initially randomly assigned fewer than 100 par-
ticipants (Balanzo 1990; Garrido 2002; Grgov 2012; Lee 1997;
Lin 1993; Lin 1999; Loizou 1991; Park 2004; Sollano 1991;
Villanueva 1993; Villanueva 1996).
Study participants were adults with a mean age greater than
54 years. Age was not reported in Lee 1997, Sollano 1991 or
Villanueva 1996. A predominance of male participants was noted
in all included studies. Lee 1997, Sollano 1991 and Villanueva
1996 did not report themale-to-female ratio. More duodenal than
gastric ulcers were included in the trials that reported this charac-
teristic; Lee 1997 and Villanueva 1996 did not report this charac-
teristic.
The Forrest classification of type of bleeding group was reported
in all studies, but only 13 studies (Balanzo 1990; Choudari 1994;
Chung 1993; Chung 1996; Chung 1997; Chung 1999; Garrido
2002; Kubba 1996; Lin 1993; Loizou 1991; Park 2004; Pescatore
2002; Villanueva 1993) reported ulcers categorised by type of
bleeding.
Further details of each study can be found in Characteristics of
included studies.
Interventions
We recorded any dosage of epinephrine and second endoscopic
treatment applied. Medical treatments given as adjuncts were dif-
ferent in each study or were not specified. However, the best treat-
ment for haemorrhage from peptic ulcer is the endoscopic treat-
ment that we analysed in the meta-analysis.
Twelve studies compared epinephrine versus epinephrine plus a
second injected agent. The second injected agents were thrombin
in Balanzo 1990 and Kubba 1996; fibrin glue in Pescatore 2002;
ethanolamine in Choudari 1994; sodium tetradecyl sulphate in
Chung 1993; ethanol in Chung 1996, Lee 1997 and Lin 1993;
polidocanol in Garrido 2002, Villanueva 1993 and Villanueva
1996; and ethoxy sclerol in Sollano 1991.
Three studies compared epinephrine versus epinephrine plus heat:
Chung 1997 used a heat probe, Lin 1999 used bipolar electroco-
agulation and Loizou 1991 employed neodymium-doped yttrium
aluminiumgarnet (Nd:YAG) laser photocoagulation.The remain-
ing four studies used a mechanical method such as haemoclips (Lo
2006; Chung 1999; Grgov 2012) or band ligation (Park 2004).
The dosage of epinephrine and the method of injection used were
stated in the study reports. Two studies used the same dosage of
epinephrine in both groups-epinephrine alone or combined treat-
ment-independently ofwhether the haemorrhage stopped (7.5mL
Choudari 1994; 10 mL Loizou 1991). Another study (Lo 2006)
injected epinephrine until haemostasis or to a maximum dose of
20 mL of epinephrine in both groups, independently of achieving
haemostasis. The remaining included studies investigated the use
of injected epinephrine until haemostasis was achieved. Seven in-
cluded studies did not specify the dosage (Balanzo 1990; Chung
1993; Chung 1996; Chung 1999; Garrido 2002; Park 2004;
Villanueva 1996). In the remaining studies (Chung 1997; Grgov
2012; Kubba 1996; Lee 1997; Lin 1993; Lin 1999; Pescatore
2002; Sollano 1991; Villanueva 1993), the volume of epinephrine
used was reported (Characteristics of included studies).
Ten studies performed one or more scheduled second-look en-
doscopies 24 to 72 hours after the initial technique was ap-
plied (Balanzo 1990; Choudari 1994; Chung 1993; Chung 1996;
Chung 1997; Chung 1999; Park 2004; Pescatore 2002; Sollano
1991; Villanueva 1993) (n = 1203). When active bleeding or per-
sistent high-risk stigmata (Forrest Ia-Ib-IIa-IIb) were observed, a
second therapeutic procedure was performed.Nine studies did not
schedule second-look endoscopy (Lo 2006; Garrido 2002; Grgov
2012; Kubba 1996; Lee 1997; Lin 1993; Loizou 1991; Park 2004;
Villanueva 1996).
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Outcomes
Primary outcome
Persistent and recurrent bleeding
We used the following terms: Persistent bleeding occurs when no
initial haemostasis was achieved, and recurrent bleeding is a new
bleed after initial haemostasis; in trials in which all participants
had successful initial haemostasis, the number relates only to the
number with recurrent bleeding (as persistent bleeding cannot
occur if initial haemostasis is successful).
In most studies, the primary endpoint was defined as endoscopic
therapy failure, that is, a combination of persistent haemorrhage
and recurrence during follow-up (further bleeding). Clinical cri-
teria used for presuming further bleeding differed between stud-
ies (Characteristics of included studies). Recurrent bleeding in
the outcome ’with second-look endoscopy’ was confirmed endo-
scopically, and 10 studies reported this outcome (Balanzo 1990;
Choudari 1994; Chung 1993; Chung 1996; Chung 1997; Chung
1999; Lin 1993; Pescatore 2002; Sollano 1991; Villanueva 1993);
otherwise rebleeding rates included both endoscopic and clini-
cally evident rebleeding. Analyses were also performed on included
studies that reported data for persistent haemorrhage and recur-
rence separately during follow-up.
Fourteen studies reported initial failure of haemostasis and recur-
rent bleeding separately (Balanzo 1990; Lo 2006; Chung 1993;
Chung 1996; Chung 1997; Chung 1999; Grgov 2012; Lee 1997;
Lin 1993; Lin 1999; Loizou 1991; Park 2004; Sollano 1991;
Villanueva 1993). The remaining five studies did not distin-
guish between persistent and recurrent bleeding (Choudari 1994;
Garrido 2002; Kubba 1996; Pescatore 2002; Villanueva 1996).
Fourteen studies randomly assigned participants who reported
bleeding rates when peptic ulcers were actively bleeding (spurting
Forrest Ia or oozing Forrest Ib) (Balanzo 1990; Choudari 1994;
Chung 1993; Chung 1996; Chung 1997; Chung 1999; Garrido
2002; Kubba 1996; Lee 1997; Lin 1993; Loizou 1991; Park 2004;
Pescatore 2002; Villanueva 1993).
Nine studies with a total of 448 participants provided data on pep-
tic ulcers with a non-bleeding visible vessel (Forrest IIa) (Balanzo
1990; Choudari 1994; Chung 1993; Garrido 2002; Kubba 1996;
Loizou 1991; Park 2004; Pescatore 2002; Villanueva 1993). Only
four studies (Lo 2006;Garrido2002;Grgov 2012; Pescatore 2002)
included participants with adherent clot (Forrest IIb), although Lo
2006 and Grgov 2012 did not report results according to Forrest
category, and therefore results from only 30 participants appear in
our analyses.
Secondary outcomes
Surgery and mortality
Criteria for emergency surgery were not specified in most studies.
Thirty-day mortality and in-hospital mortality were the criteria
used most often for defined mortality (Characteristics of included
studies).
The need for emergency surgery was evaluated in 18 studies (1841
participants) (Balanzo 1990; Lo 2006; Choudari 1994; Chung
1993; Chung 1996; Chung 1997; Chung 1999; Grgov 2012;
Kubba 1996; Lee 1997; Lin 1993; Lin 1999; Loizou 1991; Park
2004; Pescatore 2002; Sollano 1991; Villanueva 1993; Villanueva
1996). Garrido 2002 did not specify surgery rates in each group,
only total rate.
The criteria for mortality rate were also different between studies.
Some studies used hospital mortality; others used 30-daymortality
or did not specify the criteria for mortality. The mortality rate
was evaluated in 18 studies (Balanzo 1990; Lo 2006; Choudari
1994; Chung 1993; Chung 1996; Chung 1997; Chung 1999;
Grgov 2012; Kubba 1996; Lee 1997; Lin 1993; Lin 1999; Loizou
1991; Park 2004; Pescatore 2002; Sollano 1991; Villanueva 1993;
Villanueva 1996); only Garrido 2002 did not report mortality.
In addition, 12 studies reported complications that occurred in the
study population (Lo 2006; Chung 1993; Chung 1997; Chung
1999; Grgov 2012; Kubba 1996; Lin 1993; Lin 1999; Loizou
1991; Pescatore 2002; Sollano 1991; Villanueva 1993).
Excluded studies
A total of 20 studies were excluded from the review; 13 were
excluded before this update was performed (Buffoli 2001; Chua
2001; Chung 1990; Chung 1992; Chung 1997a; DeGoede 1998;
Dedeu 2003; Ell 2002; Gevers 2002; Male 1999; Pescatore 1999;
Sabat 1998; Wehrmann 1994), and we excluded a further seven
studies in 2014 (Chittmittrapap 2010; Grgov 2013; Karaman
2011; Lecleire 2009; Ljubicic 2012; Taghavi 2009; Tsoi 2009).
The main reasons for exclusion of studies were as follows: non-
randomised studies (Buffoli 2001; Chittmittrapap 2010; Chua
2001; Tsoi 2009); preliminary results published later in another
article (Chung 1990; Chung 1992; Chung 1997a; De Goede
1998; Male 1999; Pescatore 1999); impossible to extract data
(Dedeu 2003; Ell 2002); did not fit our criteria for intervention,
that is, did not compare epinephrine alone versus epinephrine
plus a second agent (Gevers 2002; Grgov 2013; Karaman 2011;
Ljubicic 2012; Taghavi 2009); participants did not fit our inclu-
sion criteria (Lecleire 2009); or important methodological prob-
lems were noted within the study (Sabat 1998; Wehrmann 1994)
(see Characteristics of excluded studies).
Risk of bias in included studies
A summary of the risk of bias across studies is given in Figure 2
and Figure 3.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Randomisation was adequately described in only 10 of the in-
cluded studies (Lo 2006;Chung 1993;Chung 1996;Chung 1997;
Chung 1999; Lin 1993; Lin 1999; Park 2004; Pescatore 2002;
Villanueva 1993) and was judged as unclear in the remaining stud-
ies. Allocation concealment was adequate in 13 studies and was
judged as unclear in six studies (Balanzo 1990; Garrido 2002;
Grgov 2012; Lee 1997; Sollano 1991; Villanueva 1996).
Blinding
The studies were not double blind because the endoscopist must
know the technique to be applied.
Incomplete outcome data
Only six studies were judged as unclear for incomplete outcome
data (Balanzo 1990; Choudari 1994; Garrido 2002; Lee 1997;
Lin 1993; Pescatore 2002); all remaining studies were judged as
having low risk of bias.
Selective reporting
A total of 11 studies were rated as having low risk of bias for
selected outcome reporting (Balanzo 1990; Lo 2006; Choudari
1994; Chung 1993; Chung 1996; Kubba 1996; Lin 1993; Lin
1999; Park 2004; Pescatore 2002; Sollano 1991). The remaining
studies were rated as having unclear risk of bias. However in the
absence of initial study protocols, it is not clear whether all studies
reported outcomes as prespecified in the trial protocol.
Other potential sources of bias
Other potential sources of bias were noted in the design of studies
in terms of interventions used and outcomes assessed. The dif-
ferent treatment strategies used could bias results, as some may
appear more favourable in terms of achieving haemostasis, such as
the technique used by Lo 2006, in which epinephrine was injected
until haemostasis was achieved or until a maximum dose of 20
mL of epinephrine was given in both groups, independently of
achieving haemostasis. It is difficult, however, to establish whether
this method could decrease the frequency of recurrence.
Some studies used different definitions of haemorrhage. However,
all studies included in the meta-analysis that reported rebleeding
criteria were very similar, suggesting that the definition of rebleed-
ing was not a source of bias. As explained, outcome criteria in all
studies were very similar, so we believe that these data did not bias
study results.
The mortality rate was also different between studies using dif-
ferent criteria. Some studies used hospital mortality, while others
used 30-day mortality or did not specify the criteria for mortality.
This made comparison of mortality rates difficult and hindered
conclusions about the rate of mortality resulting from haemor-
rhage in people with ulcers. Moreover, data on previous morbidity
among study participants oftenwere not provided in study reports.
Effects of interventions
See:Summary offindings for themain comparisonEpinephrine
versus epinephrine and any second endoscopic method in high-
risk bleeding ulcers
We use the following terms: Persistent bleeding occurs when no
initial haemostasis is achieved, and recurrent bleeding is a new
bleed after initial haemostasis. In trials in which all had successful
haemostasis, the number relates only to the number with recurrent
bleeding (as bleeding cannot be persistent if the initial haemostasis
is successful).
In the text below, an I² statistical value for heterogeneity is reported
as follows: 30% to 60%: may represent moderate heterogeneity;
50% to 90%: may represent substantial heterogeneity; 75% to
100%: shows considerable heterogeneity.
Numbers given show the total numbers of participants in the anal-
ysis. When it was possible to calculate an effect size, these values
were reported with 95% confidence intervals. When the calcu-
lated effect size was statistically significant (P value < 0.05), we
stated whether the result favours the intervention or the control
condition.
We have summarised results below under headings corresponding
to the primary and secondary outcomes outlined in the section
entitled Types of outcome measures.
COMPARISON 1. Epinephrine versus epinephrine
and any second endoscopic method
Initial failure of haemostasis (persistent bleeding)
For this outcome, we found 14 relevant trials that provided sepa-
rate data on participants who did not achieve initial haemostasis
(Balanzo 1990; Chung 1993; Chung 1996; Chung 1997; Chung
1999; Grgov 2012; Lee 1997; Lin 1993; Lin 1999; Lo 2006;
Loizou 1991; Park 2004; Sollano 1991; Villanueva 1993) (n =
1380). No significant difference was noted between epinephrine
and epinephrine and any second endoscopic method (RR random
0.77, 95% CI 0.42 to 1.4; Analysis 1.1).
Recurrent bleeding only (bleeding after initial haemostasis)
For this outcome, we found 14 relevant trials (Balanzo 1990;
Chung 1993; Chung 1996; Chung 1997; Chung 1999; Grgov
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2012; Lee 1997; Lin 1993; Lin 1999; Lo 2006; Loizou 1991;
Park 2004; Sollano 1991; Villanueva 1993) (n = 1333). A statisti-
cally significant difference was reported between epinephrine and
epinephrine and any second endoscopic method favouring com-
bined therapy (RR random0.53, 95% CI 0.35 to 0.81, P value
0.03; Analysis 1.2). This outcome had moderate levels of hetero-
geneity (Chi2 = 21.92, df = 13, P value 0.06, I2 = 41%).
Recurrrent and persistent bleeding overall rates with or
without second-look endoscopy
All articles that compared substances administered by endoscopic
injection (sclerosants such as ethanol, polidocanol, ethanolamine
or tetradecyl sulphate; adhesive agents such as cyanoacrylate;
and thrombotic substances such as fibrin glue or thrombin),
epinephrine plus thermal agents and epinephrine plus a mechan-
ical method such as clips were analysed together. All studies re-
ported this outcome, that is, clinically diagnosed and/or endo-
scopically confirmed rebleeding (19 relevant trials; Balanzo 1990;
Choudari 1994; Chung 1993; Chung 1996; Chung 1997; Chung
1999; Garrido 2002; Grgov 2012; Kubba 1996; Lee 1997; Lin
1993; Lin 1999; Lo 2006; Loizou 1991; Park 2004; Pescatore
2002; Sollano 1991; Villanueva 1993; Villanueva 1996) (n =
1926). A statistically significant difference between epinephrine
and epinephrine and any second endoscopic method favoured
combined therapy (RR random 0.57, 95% CI 0.43 to 0.76, P
value 0.0001; Analysis 1.3). This outcome had moderate levels of
heterogeneity (Chi2 = 29.11, df = 18, P value 0.05, I2 = 38%).
Recurrent and persistent bleeding and second-look
endoscopy
With second-look endoscopy (endoscopically confirmed
persistent or recurrent bleeding)
Ten studies performed one or more scheduled second-look en-
doscopies 24 to 72 hours after the initial technique was ap-
plied (Balanzo 1990; Choudari 1994; Chung 1993; Chung 1996;
Chung 1997; Chung 1999; Park 2004; Pescatore 2002; Sollano
1991; Villanueva 1993) (n = 1203). When active bleeding or per-
sistent high-risk stigmata (Forrest Ia-Ib-IIa-IIb) were observed en-
doscopically, a second therapeutic procedure was performed. No
significant difference was noted between the numbers with endo-
scopically confirmed rebleeding in the epinephrine group and in
the epinephrine and second endoscopic method groups (RR 0.82,
95% CI 0.64 to 1.06; Analysis 1.4).
Without second-look endoscopy
Nine studies did not schedule second-look endoscopy (Lo 2006;
Garrido 2002; Grgov 2012; Kubba 1996; Lee 1997; Lin 1993;
Loizou 1991; Park 2004; Villanueva 1996) (n = 720). A statisti-
cally significant difference in the numbers of participants with re-
bleeding (clinically diagnosed and endoscopically confirmed) be-
tween epinephrine and epinephrine and any second endoscopic
method favoured combined therapy (RR random 0.32, 95% CI
0.21 to 0.48, P value < 0.00001; Analysis 1.4).
Surgery rate
For this outcome, we found 18 relevant trials that reported the
numbers of participants who needed surgical intervention on an
emergency basis because initial haemostasis could not be obtained,
or because rebleeding occurred (Balanzo 1990; Choudari 1994;
Chung 1993; Chung 1996; Chung 1997; Chung 1999; Grgov
2012; Kubba 1996; Lee 1997; Lin 1993; Lin 1999; Lo 2006;
Loizou 1991; Park 2004; Pescatore 2002; Sollano1991;Villanueva
1993; Villanueva 1996) (n = 1841). A statistically significant dif-
ference between epinephrine and epinephrine and any second en-
doscopic method favoured combined therapy (RR random 0.68
95% CI 0.50 to 0.93, P value 0.02; Analysis 1.5).
Mortality rate
For this outcome, we found 18 relevant trials reporting mortality
as death in hospital or as a result of bleeding peptic ulcer (Balanzo
1990; Choudari 1994; Chung 1993; Chung 1996; Chung 1997;
Chung 1999; Grgov 2012; Kubba 1996; Lee 1997; Lin 1993; Lin
1999; Lo 2006; Loizou 1991; Park 2004; Pescatore 2002; Sollano
1991; Villanueva 1993; Villanueva 1996) (n = 1841). No signif-
icant difference was noted between epinephrine and epinephrine
and any second endoscopic method (RR random 0.64, 95% CI
0.39 to 1.06; Analysis 1.6).
Adverse effects of endoscopic therapy
For this outcome,we found12 relevant trials that reportedwhether
complications had occurred and the types of complications re-
ported (Chung 1993; Chung 1996; Chung 1997; Chung 1999;
Grgov 2012, Kubba 1996; Lin 1993; Lin 1999; Lo 2006; Pescatore
2002; Sollano 1991; Villanueva 1993) (n = 1281). No significant
difference was noted between epinephrine and epinephrine and
any second endoscopic method (RR random 1.25, 95% CI 0.4 to
3.96; Analysis 1.7). Details of adverse effects encountered (found
in Table 1) included perforations, mucosal injury and necrosis. In-
duction of massive bleeding requiring surgery was more frequent
in the epinephrine only group (n = 5); necrosis appeared in three
participants (two in the combined therapy group and one in the
epinephrine alone group), and perforation (three participants) was
observed in the combined therapy group. Thus, adverse events
were slightly more frequent in the combined therapy group (6/
610 participants) than in the epinephrine alone group (5/648 par-
ticipants), although this difference did not reach statistical signif-
icance.
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Recurrent and persistent bleeding according to type of
haemorrhage
Forrest Ia-Ib (spurting or oozing haemorrhage)
Thirteen studies with a total of 1019 participants reported bleed-
ing rates when peptic ulcers were actively bleeding (spurting For-
rest Ia; oozing Forrest Ib) We included participants who had
confirmed bleeding by endoscopy and those who clinically re-
bled in Analysis 1.8) (Balanzo 1990; Choudari 1994; Chung
1993; Chung 1996; Chung 1997; Chung 1999; Garrido 2002;
Kubba 1996; Lin 1993; Loizou 1991; Park 2004; Pescatore 2002;
Villanueva 1993 (n = 1019). A statistically significant difference
favoured the combined therapy group (RR 0.66, 95% CI 0.49 to
0.88, P value 0.005, I2 = 15%)
Forrest IIa (visible vessel)
Nine studies with a total of 440 participants provided data on pep-
tic ulcers with a non-bleeding visible vessel (Forrest IIa) (Balanzo
1990; Choudari 1994; Chung 1993; Garrido 2002; Kubba 1996;
Loizou 1991; Park 2004; Pescatore 2002; Villanueva 1993).
No significant difference was reported between epinephrine and
epinephrine and any second endoscopic method (RR 0.97, 95%
CI 0.47 to 1.99, I2 = 29%; Analysis 1.8).
Forrrest IIb (adherent clot)
Only four studies (Lo 2006; Garrido 2002; Grgov 2012; Pescatore
2002) included participants with adherent clot (Forrest IIb). Lo
2006and Grgov 2012 did not provide results on different Forrest
groups included in the study and so were not included in this anal-
ysis. In the epinephrine alone group, 4/15 (26.7%) presented fur-
ther bleeding versus 3/15 (20%) in the combined therapy group.
In this subgroup, we found two relevant trials (n = 30). No sig-
nificant difference between epinephrine and epinephrine and any
second endoscopic method was noted (RR random 0.75, 95% CI
0.22 to 2.6; Analysis 1.8).
COMPARISON 2. Epinephrine plus epinephrine and a
second injected agent
Recurrent and persistent bleeding
For this outcome, we found 11 RCTs (Balanzo 1990; Choudari
1994; Chung 1993; Chung 1996; Garrido 2002; Kubba 1996;
Lee 1997; Lin 1993; Pescatore 2002; Sollano 1991; Villanueva
1993) (n = 1135); no statistically significant difference favoured
combination therapy (RR0.74, 95%CI0.53 to 1.04, P value 0.08;
Analysis 2.2). This outcome had moderate levels of heterogeneity
(Chi2 = 15.66, df = 10, P value 0.11, I2 = 36%).
Surgery rate
For this outcome, we found 10 RCTs (Balanzo 1990; Choudari
1994; Chung 1993; Chung 1996; Kubba 1996; Lee 1997; Lin
1993; Pescatore 2002; Sollano 1991; Villanueva 1993) (n = 1050)
(RR 0.85, 95% CI 0.59 to 1.21; Analysis 2.2). No significant
differences were noted between epinephrine and epinephrine and
any second injected agent.
Mortality rate
For this outcome, we found 10 RCTs (Balanzo 1990; Choudari
1994; Chung 1993; Chung 1996; Kubba 1996; Lee 1997; Lin
1993; Pescatore 2002; Sollano 1991; Villanueva 1993) (n = 1050)
(RR 0.5, 95% CI 0.25 to 1.0; Analysis 2.3). A statistically signifi-
cant difference was reported between epinephrine and epinephrine
and any second injected agent.
COMPARISON 3. Epinephrine versus epinephrine
and mechanical endoscopic methods
Recurrrent and persistent bleeding
For this outcome, we found five relevant trials that reported the
efficacy of adding amechanical haemoclip to epinephrine injection
(Chung 1999;Grgov 2012; Lo 2006; Park 2004; Villanueva 1996)
(n =415). A statistically significant difference between epinephrine
and epinephrine and mechanical endoscopic methods favoured
epinephrine plus a mechanical method (RR random 0.31, 95%
CI 0.18 to 0.55, P value < 0.0001; Analysis 3.1).
Surgery rate
Five RCTs provided data on surgery rate (Chung 1999; Grgov
2012; Lo 2006; Park 2004; Villanueva 1996) (n = 415). A statisti-
cally significant difference between epinephrine and epinephrine
and mechanical endoscopic methods favoured epinephrine plus
a mechanical method (RR random 0.2, 95% CI 0.06 to 0.62, P
value 0.005; Analysis 3.2).
Mortality rate
Mortality rate was provided in five RCTs (Chung 1999; Grgov
2012; Lo 2006; Park 2004; Villanueva 1996) (n = 415). No signif-
icant difference was noted between epinephrine and epinephrine
and mechanical endoscopic methods (RR random 0.73, 95% CI
0.19 to 2.71; Analysis 3.3).
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COMPARISON 4. Epinephrine plus epinephrine and
thermal methods
Recurrent and persistent bleeding
Three studies compared epinephrine alone versus epinephrine
combined with thermal haemostatic methods (contact heat probe,
Nd:YAG laser or bipolar electrocoagulation) (Chung 1997; Lin
1999; Loizou 1991) (n = 376) (RR random 0.49, 95% CI 0.30 to
0.78, P value 0.003; Analysis 4.1). A statistically significant dif-
ference was observed between epinephrine and epinephrine and
thermal endoscopic methods.
Surgery rate
Surgery rate was given in three trials (Chung 1997; Lin 1999;
Loizou 1991) (n = 376), A statistically significant difference be-
tween epinephrine and epinephrine and thermal endoscopicmeth-
ods favoured the combination therapy group (RR random 0.45,
95% CI 0.21 to 0.95, P value 0.04; Analysis 4.2).
Mortality rate
For this outcome, we found three relevant trials (Chung 1997;
Lin 1999; Loizou 1991) (n = 376) (RR random 0.92, 95% CI
0.37 to 2.26; Analysis 4.3). No significant difference was observed
between epinephrine and epinephrine and thermal endoscopic
methods.
D I S C U S S I O N
Summary of main results
Nineteen studies including a total of 2033 initially randomly as-
signed participants were included, of which 11 used a second in-
jected agent, five used a mechanical method (haemoclips) and
three employed thermal methods.
For the comparison of epinephrine versus any second agent,
we produced meta-analyses for eight outcomes. Few participants
failed initial haemostasis, and analyses of epinephrine versus
epinephrine plus any second method failed to show differences
in achieving initial haemostasis between epinephrine alone and
epinephrine with a second endoscopic method.
Adding any second procedure significantly reduced rebleeding
rates in three analyses, that is, fewer participants in the com-
bined therapies groups experienced recurrent bleeding after initial
haemostasis (RR 0.53, 95% CI 0.35 to 0.81); fewer participants
had persistent and recurrent bleeding (with or without second-
look endoscopy) (RR 0.57, 95% CI 0.43 to 0.76) and fewer had
persistent or recurrent bleeding (without scheduled second-look
endoscopy) (RR 0.32, 95% CI 0.21 to 0.48). No difference in
rebleeding rates was seen between groups in studies that did sched-
ule second-look endoscopy.
The numbers needing emergency surgery were significantly lower
in the combined group (RR 0.68, 95% CI 0.50 to 0.93), but
mortality rates were not significantly different with either method.
Adverse events included perforations,mucosal injury and necrosis;
these events were few, and no statistically significant difference
between groups was noted.
For ulcers of the Forrest Ia or Ib type (oozing or spurting), the
addition of a second therapy significantly reduced the rebleeding
rate (RR 0.66, 95% CI 0.49 to 0.88); this difference was not seen
for type IIa (visible vessel) or type IIb (adherent clot) ulcers.
Our analyses therefore showed that the risk of further bleeding was
lower in the combination therapy groups than in the epinephrine
alone groups, regardless of which second procedure was applied.
Failure of endoscopic therapy is the main predictor of the need for
surgery and of morbidity and mortality in patients with bleeding
peptic ulcer (Brullet 1996). Therefore, it seems highly likely that
reduction of further bleeding rates decreased the need for surgery
and improved survival.
We also compared epinephrine versus epinephrine plus injected
agents, versus epinephrine plus a mechanical method and versus
epinephrine plus thermal methods separately.
For the comparison of epinephrine versus epinephrine plus any
injected method, we produced meta-analyses for three outcomes.
Fewer participants in the combination group experienced recur-
rent and persistent bleeding, but this finding was not statistically
significant. Fewer participants in the combination therapy group
died and this was statistically significant (RR 0.50, 95%CI 0.25 to
1.00), but no difference between groups was noted for the number
needing emergency surgery.
For the comparison of epinephrine versus epinephrine plus a me-
chanical method such as haemoclips, results favoured the com-
bination therapy group for recurrent or persistent bleeding (RR
0.31, 95%CI 0.18 to 0.55); fewer participants in the combination
group needed surgery (RR 0.20, 95% CI 0.06 to 0.62), but no
statistically significant difference was reported for mortality.
For the comparison of epinephrine versus epinephrine plus a ther-
mal method, results favoured combined therapy for recurrent and
persistent bleeding (RR0.49, 95%CI0.30 to 0.78) and for surgery
(RR 0.92, 95% CI 0.37 to 2.26), but no statistically significant
difference was reported for mortality.
Our updated review with new data confirms the results published
in our previous review (Vergara 2007).
Overall completeness and applicability of
evidence
One limitation of this review is that definitions for haemorrhage,
surgery and death were not the same in the different studies
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(Characteristics of included studies). Marked heterogeneity ob-
served in defining further bleeding among studies precluded the
definition of a homogeneous, predetermined criterion for the
primary endpoint. We therefore accepted the definition estab-
lished for each study. Further bleeding definitions are shown in
Characteristics of included studies. As the analysis includes only
randomised, comparative studies, the criteria were similar for the
two groups (epinephrine alone and combined therapy) in each
study, thus allowing further comparison. Furthermore, endoscopic
confirmation of bleeding was required for studies that reported
second-look endoscopy, thus reducing heterogeneity. Criteria for
mortality rate were different between studies. Some studies used
hospital mortality as a key, and others used 30-day mortality or did
not specify the mortality criteria applied. This makes it difficult
to extract definitive conclusions about mortality rates in haemor-
rhage from those in ulcer disease. Moreover, characteristics of the
co-morbidities of participants were not included in the results of
most of the studies.
Medical treatments were also different between studies or were not
specified. However, the best treatment for bleeding from a peptic
ulcer is the endoscopic treatment that we analysed in the present
meta-analysis.
One important point to state involves the dosage of epinephrine
and the methodological process used in each study. The dosage
of epinephrine used was detailed in Characteristics of included
studies. Seven included studies did not specify the dosage (Balanzo
1990; Chung 1993; Chung 1996; Chung 1999; Garrido 2002;
Park 2004; Villanueva 1996). Two studies used the same dosage of
epinephrine for both groups independently of whether haemor-
rhage stopped (Choudari 1994; Loizou 1991). Another study (Lo
2006) injected epinephrine until haemostasis or to a maximum
dose of 20 mL of epinephrine in both groups, independently of
achieving haemostasis.
Comparisons of epinephrine versus epinephrine plus a specific sec-
ond method also raise some unanswered questions. First, although
one might consider that the efficacy of injecting a second agent
is similar to that achieved with thermal and mechanical methods,
this interpretation should be treated with extreme caution. The
only conclusion that can be drawn from our meta-analysis is that,
whichever second treatment is used, combined therapy seems to
work better than epinephrine alone.However, we cannot conclude
that a particular form of treatment is equal or superior to another.
Indeed, an earlier meta-analysis evaluating endoscopic therapy for
bleeding peptic ulcers demonstrated that all methods of control-
ling bleeding in peptic ulcers (thermal devices, injectable agents
such as sclerosants and thrombin/fibrin glue and haemoclips) were
effective, with no single modality determined to be superior (Laine
2009). There are two main reasons for this. First, the subgroups
(further injection, thermal methods or mechanical methods) in-
clude different procedures that may present heterogeneous activ-
ity. In fact, each endoscopic treatment presents different character-
istics: Epinephrine produces vasoconstriction, vessel compression
and platelet aggregation, but it does not seem to induce permanent
thrombosis in blood vessels (Lin 2002). Sclerosant agents such as
polidocanol or ethanol can produce thrombosis of vessels favour-
ing haemostasis, although they may also induce significant tissue
injury (Randall 1989; Ritgeers 1989). Whether human thrombin
injection could reduce the risk of tissue damage remains unclear,
and thrombin is more expensive than other additional treatments
(Laine 2003). Thermal agents produce thrombosis of vessels and
risk damaging tissue. Among them, laser photocoagulation seems
to be associated with higher risks of perforation, optical hazard,
high cost and imperfect haemostatic effect. Multi-polar electroco-
agulation and heater probe thermocoagulation have been reported
to produce excellent results; they are also less expensive and are
more easily portable than laser methods (Llach 1996). Mechanical
methods close the vessel. They were also associated with few com-
plications, but technical difficulty was associatedwith applying the
haemoclip to the posterior wall of the proximal body and cardia of
the stomach (Grgov 2012), and to the posterior wall of the duo-
denum, because of the requirement that the haemoclip meet the
lesion at a right angle (Chung 1999; Simoens 2001). A meta-anal-
ysis compared haemoclip versus other methods to investigate the
possible benefits of haemoclips versus other endoscopic methods.
The evidence showed no differences between them (Yuan 2008).
Even more important, the statistical treatments used in our meta-
analyses are not designed to compare additional treatments head
to head. In fact, we lack randomised trials comparing different
additional treatments after epinephrine injection, although some
recent studies are available (e.g. Grgov 2013; Karaman 2011;
Taghavi 2009), and we must await analysis of comparative stud-
ies to establish which is the best therapy when combined with
epinephrine.
Our review did not determine whether combined therapy is better
than sclerosants, thermal methods or mechanical methods alone.
Little evidence in the literature suggests that this is the case. In a
small study, Lin 1999 found that combined therapy seems better
than bipolar electrocoagulation alone. Also, a recent meta-analy-
sis concluded that combined injection is superior to a sclerosant
alone (Rollhauser 2000). In any event, the clinical relevance of this
question may be minor.
One of the major fears associated with using combined therapy
involves the possible risk of gastric wall necrosis or perforation or
both. The present meta-analysis shows that the risk of significant
complications is very low. This review failed to find evidence of a
difference in complication rates between groups. When the com-
plications are examined in detail, it can be seen that induction
of massive bleeding requiring surgery was more frequent in the
epinephrine group, whereas gastric wall necrosis or perforation
was more common in the combined therapy group. This possible
small increase in the risk of perforation or necrosis is clearly com-
pensated for by the benefits derived from reducing further bleed-
ing, which result in a significant decrease in the need for surgery
and in mortality; therefore this risk is not a reason for avoiding
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combined therapy.
Epinephrine injection is cheap, easy to perform and safe. In ad-
dition, according to our analysis, epinephrine seems as good as
combined therapy for achieving initial haemostasis. By control-
ling active bleeding, it could allow a better endoscopic view and
more accurate targeting of additional therapy. Therefore, medical
or economic arguments against epinephrine injection are few.
Quality of the evidence
Of the 19 trials included in this review, some had limitations in
design or implementation, but most were clear about important
quality criteria including randomisation and allocation conceal-
ment, sequence generation and blinding.Our risk of bias estimates
show that overall most studies were not at high risk of bias in any
of the domains that we assessed. It should be noted that we did
not rate performance bias because it is not possible to blind partic-
ipants and personnel in studies of this nature. Although the type
of study did not allow a double-blind trial (Figure 2), rebleeding,
surgery and mortality were not dependent on subjective observa-
tion.
The meta-analysis involved a large number of well-designed stud-
ies, but for most outcomes, the quality of the evidence was rated
as moderate, and further research is likely to have an important
impact on our confidence in the estimate of effect andmay change
the estimate. We summarised the quality of the studies in Sum-
mary of findings table 1. When we downgraded the evidence to
moderate quality, we did so because few events were reported; this
was the case for the outcomes of surgery, mortality and adverse
effects. The included studies involved relatively few participants,
but larger populations are difficult to achieve in this type of trial.
Some imprecision was noted (wide confidence intervals), and the
results of some meta-analyses showed low to moderate levels of
statistical heterogeneity (inconsistency). One explanation for this
may be the differences noted between trials (populations, defini-
tions of outcomes such as in-hospital or 30-day mortality and def-
initions of rebleeding), as discussed above.
Potential biases in the review process
One limitation of our review is that despite exhaustive searching,
it is difficult to be certain that every published and unpublished
study was identified. We acknowledge that there is always a risk
that some studies were not identified. However for the studies that
we identified, the qualitywas rated asmoderate formost outcomes,
and because of the serious nature of this condition, incidences of
adverse effects were reported in many trials.
Agreements and disagreements with other
studies or reviews
The findings of our updated review are in agreement with the
recommendations provided in three major clinical guidelines pro-
duced since the first published version of this review. Combined
therapy of epinephrine plus a second endoscopic agent (e.g. bipo-
lar electrocoagulation, heater probe, sclerosant, clips) for the treat-
ment of patients with high-risk bleeding peptic ulcers (Laine 2012;
NICE 2012;Hwang 2012) is themain recommendation for active
bleeding or non-bleeding visible vessels.
As far as second-look endoscopy is concerned, one meta-analysis
showed that although scheduled second-look endoscopies reduced
the rebleeding rate, they did not decrease the need for surgery
nor mortality (Marmo 2003). It was also suggested that selective
second-look endoscopy for selected high-risk patients could be a
cost-effective approach (Spiegel 2003). However, this strategy ex-
poses patients to uncomfortable and somewhat risky procedures
and increases the workload of the endoscopy unit. Results of the
present study did not confirm that second-look endoscopy dimin-
ished the risk of rebleeding. For all of these reasons, it remains
unclear whether second-look endoscopy offers any added benefit
to combined therapy associated with proton pump inhibitor infu-
sion. This finding is in agreement with current guidelines on the
management of acute non-variceal upper gastrointestinal bleed-
ing. In the NICE 2012 guideline, the recommendation is to “con-
sider a repeat endoscopy, with treatment as appropriate” (further
endoscopic treatment or emergency surgery),“for all patients at
high risk of re-bleeding, particularly if there is doubt about initial
haemostasis at the first endoscopy.” The AGA guideline (Laine
2012) does not recommend routine second-look endoscopy 24
hours after initial endoscopic haemostatic therapy but says that
this should be offered for patients with clinical evidence of recur-
rent bleeding, and in these cases, haemostatic therapy should be
applied for those with greater risk of stigmata of haemorrhage.
Routine second-look endoscopy, defined as a planned endoscopy
performed within 24 hours of the initial endoscopy, in patients
who have received adequate endoscopy is not recommended by
the ASGE in its 2012 guideline (Chung 1999; Hwang 2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The present study shows that adding a second endoscopic proce-
dure after epinephrine injection reduces the rate of recurrence in
patients with high-risk bleeding peptic ulcer. This study also shows
that adding any second endoscopic method reduces the need for
surgery. In view of the evidence, and while we await the results of
further studies, combined therapy should be considered the stan-
dard procedure in high-risk peptic ulcer haemorrhage (Forrest Ia,
Ib, IIa).
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Implications for research
The current evidence shows that addition of a second endoscopic
method to epinephrine injection is better than epinephrine in-
jection alone in high-risk bleeding peptic ulcers, in terms of pre-
venting both rebleeding and the need for emergency surgery. Fu-
ture research should investigate the best endoscopic method that,
when associated with epinephrine, achieves low rebleeding rates,
reduced need for surgery and prevention of mortality and pro-
cedure-related adverse effects when standardised outcome criteria
such as use of a scheduled second endoscopy and criteria for re-
bleeding are used, and whether this was confirmed endoscopically.
Further systematic reviews and meta-analyses should assess such
head-to-head comparisons to compare the efficacy of additional
treatments.
Other therapeutic approaches, such as use of a high-dose proton
pump inhibitor or second-look endoscopy, could influence the
efficacy of combined therapy. Use of high-dose proton pump in-
hibitors for patients with bleeding peptic ulcers is gaining accep-
tance. Evidence clearly suggests that these drugs reduce the risk
of rebleeding (Gisbert 2001). However, many points remain un-
clear, such as the cost-effectiveness of this approach, the ideal drug
dosage to be used and whether this strategy should be reserved
for patients at high risk of rebleeding. Both combined endoscopic
therapy and proton pump inhibitor infusion are safe and comfort-
able for the patient. Therefore, although the extent of the benefit
of combining the two approaches remains uncertain, this strategy
seems reasonable until additional evidence becomes available.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Balanzo 1990
Methods Randomised, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 64)• Age (years): 65 (mean)
• Sex (male/female): 38/26
• Duodenal/gastric ulcer: 20/41
• Forrest group: Ia/Ib = 24, IIa = 40
Interventions Interventions
• Primary intervention: epinephrine injection vs epinephrine injection plus thrombin
injection. No specification about how many different endoscopists participated in the
intervention process
• Medical treatment: not specified
• Second-look endoscopy: yes
• Epinephrine volume: not specified
Outcomes Outcomes assessed
Rebleeding rates, surgery rate and mortality
• Mortality criteria: not specified
• Bleeding criteria: not specified
• Emergency surgery rates
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study authors did not explain the method used for
sequence generation
Allocation concealment (selection bias) Unclear risk Study authors did not explain the method used for
allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done. Blinding is virtually impossible in studies
on endoscopic treatment. Review authors believe
that this did not introduce significant bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk n = 64 participants entered the study. For the
outcome of haemostasis, all participants were ac-
counted for. It is unclear why only 25 (group A) and
24 participants (group B) received an elective en-
doscopy; the outcome of participants not receiving
a second (elective) endoscopy is also unclear
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Balanzo 1990 (Continued)
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Choudari 1994
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 107)
• Age (years): 68.5 (median)
• Sex (male/female): 68/39
• Duodenal/gastric ulcer: 63/44
• Forrest group: Ia/Ib = 57, IIa = 50 (with high-risk stigmata (Forrest Ia-Ib-IIa))
Interventions Interventions
• Primary intervention: epinephrine injection (n = 55) vs epinephrine injection plus
ethanolamine (n = 52). Only 1 endoscopist carried out the procedures
• Medical treatment: H2 antagonists
• Second-look endoscopy: yes
• Epinephrine volume: 7.5 mL in each group
Outcomes Outcomes assessed
Rebleeding rate, surgery rate, units of blood transfused, duration of hospital admission
and mortality
• Mortality criteria: 30-day mortality
• Bleeding criteria: fresh hematemesis or melena plus shock or fall in haemoglobin > 2
g/dL
• Emergency surgery
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified
Allocation concealment (selection bias) Low risk Quote: “were then randomised by opening a
sealed envelope to receive... ” (pages 608-609)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done. Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors believe that this did not introduce signif-
icant bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No missing outcome data: 107 participants
were randomly assigned; however 5 patients
who were actively bleeding from peptic ulcers
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Choudari 1994 (Continued)
were not included because the bleeding point
was not identified, or initial haemostasis could
not be achieved by epinephrine; a further 2 pa-
tients were excluded because
their ulcers were inaccessible to injection. It is
unclear whether these participants were ran-
domly assigned but were not included in the
analyses, or whether they were not randomly
assigned. Outcomes were presented for all ran-
domly assigned participants
Selective reporting (reporting bias) Low risk The published report includes all expected out-
comes, including those that were prespecified
Chung 1993
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 200)
• Age (years): 54.5 (mean)
• Sex (male/female): 138/58
• Duodenal/gastric ulcer: 117/75
• Forrest group: Ia = 62, Ib = 134
Interventions Interventions
• Primary intervention: epinephrine injection (n = 99) vs epinephrine injection plus
sodium tetradecyl sulphate (n = 101)
• Medical treatment: ranitidine 50 mg/6 h intravenously
• Second-look endoscopy: yes
• Epinephrine volume: not specified
Outcomes Outcomes assessed
Rebleeding rate, surgery rate, hospital stay, transfusion requirements and mortality
• Mortality criteria: hospital mortality
• Bleeding criteria: fresh hematemesis or melena plus shock or fall in haemoglobin > 2
g/dL
• Emergency surgery
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number list generated by computer
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Chung 1993 (Continued)
Allocation concealment (selection bias) Low risk Sealed and numbered envelopes
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quote: (abstract p 611): “After the procedure
the patients were transferred to the surgical gas-
troenterology ward and were treated by sur-
geons who were unaware of the mode of treat-
ment”
Criteria: blinding was incomplete, as it is virtu-
ally impossible in studies on endoscopic treat-
ment. Review authors believe that this did not
introduce significant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data: 200 participants
were randomly assigned. Outcomes were pre-
sented for all those randomly assigned, includ-
ing details of n = 4 who were excluded after
randomisation and those lost to follow up (n
= 13) or who did not return for follow-up to
determine ulcer healing 4 weeks after discharge
Selective reporting (reporting bias) Low risk The published report includes all expected out-
comes, including those that were prespecified
Chung 1996
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 160)
• Age (years): 55.2 (mean)
• Sex (male/female): 118/42
• Duodenal/gastric ulcer: 108/51
• Forrest group: (Forrest Ia-Ib) Ia = 35, Ib = 125
Interventions Interventions
• Primary intervention: epinephrine injection (n = 81) vs epinephrine injection plus
ethanol injection (n = 79)
• Medical treatment: H2 antagonists
• Second-look endoscopy: yes
• Epinephrine volume: not specified
Outcomes Outcomes assessed
Rebleeding rate, surgery rate and mortality
• Mortality criteria: hospital mortality
• Bleeding criteria: not specified
Emergency surgery (for uncontrolled arterial bleeding)
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Chung 1996 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The treatment option had been deter-
mined by a computer generated random num-
ber list” (page 592)
Allocation concealment (selection bias) Low risk Quote: “We randomised patients into two
groups by opening a sealed envelope contain-
ing the treatment option for each” (page 592)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done
Criteria: Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors believe that this did not introduce signif-
icant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nomissing outcome data: 15 participants were
excluded before randomisation (reasons given),
160 participants were randomly assigned. Out-
comes were presented for all those randomly
assigned, along with details of loss to follow-up
Selective reporting (reporting bias) Low risk The published report includes all expected out-
comes, including those that were prespecified
Chung 1997
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 276)
• Age (years): 58.5 (mean)
• Sex (male/female): 187/89
• Duodenal/gastric ulcer: 176/87
• Forrest group: Ia = 58, Ib = 212
Interventions Interventions
• Primary intervention: epinephrine injection (n = 136) vs epinephrine injection and
heat probe (n = 140)
• Medical treatment: ranitidine
• Second-look endoscopy: yes
• Epinephrine volume: 9.5 vs 10.1
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Chung 1997 (Continued)
Outcomes Outcomes assessed
Rebleeding rate, length of hospital stay, requirement for blood transfusion, surgery rate
and mortality
• Mortality criteria: hospital mortality
• Bleeding criteria: not specified
• Emergency surgery
Notes Outcomes assessed
Rebleeding rate, surgery rate and mortality
• Mortality criteria: hospital mortality
• Bleeding criteria: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisations took place at the time
of endoscopy when actively bleeding ulcers
were seen. The endoscopy nurse then opened
a sealed envelope containing the treatment op-
tion, which had previously been determined by
a random number list generated by a computer.
Treatment was concealed from the endoscopist
when the patient was admitted into the trial”
(page 1308)
Comment: adequate
Allocation concealment (selection bias) Low risk Quote: “Randomisations took place at the time
of endoscopy when actively bleeding ulcers
were seen. The endoscopy nurse then opened
a sealed envelope containing the treatment op-
tion, which had previously been determined by
a random number list generated by a computer.
Treatment was concealed from the endoscopist
when the patient was admitted into the trial”
(page 1308)
Comment: adequate
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done
Blinding is virtually impossible in studies on
endoscopic treatment. Review authors believe
that this did not introduce significant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nomissing outcomedata: Randomisation took
place at the time of endoscopy when actively
bleeding ulcers were seen. 276 randomly as-
signed, Six patients were excluded after ran-
domisation (n = 2 in epinephrine; n = 4 in
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Chung 1997 (Continued)
combined therapy), as their ulcers were subse-
quently found to be malignant
Selective reporting (reporting bias) Unclear risk The published report includes all expected out-
comes, including those that were prespecified
Chung 1999
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 124)
• Age (years): 55.5 (mean)
• Sex (male/female): 69/14
• Duodenal/gastric ulcer: 20/61
• Forrest group: Ia = 8, Ib = 27, IIa = 48
Interventions Interventions
• Primary intervention: epinephrine injection (n = 41) vs epinephrine injection plus
haemoclip (n = 42) vs haemoclip only group (n = 41)
• Medical treatment: not specified
• Second-look endoscopy: yes
• Epinephrine volume: not specified
• Emergency surgery
Outcomes Outcomes assessed
Rebleeding rate, surgery rate and mortality
• Mortality criteria: hospital mortality
• Bleeding criteria: fresh hematemesis or melena plus shock or transfusion > 8 U
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The procedure performed was ran-
domly chosen by means of drawing a single
number (1 to 3) contained in sequentially num-
bered opaque envelopes” (page 14)
Allocation concealment (selection bias) Low risk Quote: “The procedure performed was ran-
domly chosen by means of drawing a single
number (1 to 3) contained in sequentially num-
bered opaque envelopes” (page 14)
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Chung 1999 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done
Criteria: Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors believe that this did not introduce signif-
icant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data: 143 participants
were randomly assigned. Nineteen participants
could not undergo follow-up endoscopic ex-
aminations because of personal objections or
transfer to other hospitals
Selective reporting (reporting bias) Unclear risk The published report includes all expected out-
comes, including those that were prespecified
Garrido 2002
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 85)
• Age (years): 63.1 (mean)
• Sex (male/female): 50/35
• Duodenal/gastric ulcer: 27/58
• Forrest group: Ia/Ib = 25, IIa = 52, IIb = 8
Interventions Interventions
• Primary intervention: epinephrine injection vs epinephrine injection and polidocanol
injection
• Medical treatment: not specified
• Second-look endoscopy: no
• Epinephrine volume: not specified
Outcomes Outcomes assessed
Rebleeding rate
• Mortality criteria: not specified
• Bleeding criteria: haematemesis or fresh melena
• Emergency surgery (assessed for whole group, but no separate data for the n = 85 cases
randomly assigned)
Notes Spanish language report
Risk of bias
Bias Authors’ judgement Support for judgement
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Garrido 2002 (Continued)
Random sequence generation (selection
bias)
Unclear risk Study authors did not explain sequence gener-
ation
Comment: unclear
Allocation concealment (selection bias) Unclear risk Study authors did not explain allocation con-
cealment
Comment: unclear
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done
Criteria: Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors believe that this did not introduce signif-
icant bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear whether n = 340 participants were
randomly assigned or only the n = 85 reported
in this publication who were treated endoscop-
ically. Reporting of outcomes and numbers in
each group at each time point is unclear, for ex-
ample, 3 participants died as a result of haem-
orrhage, but it is not clear which therapy they
received
Selective reporting (reporting bias) Unclear risk It is unclearwhether all outcomeswere reported
Grgov 2012
Methods Randomised, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 58)
• Age (years): 62.2 (epinephrine); 65.0 (combination therapy) mean
• Sex (male/female): 43/15
• Duodenal/gastric ulcer: 30/28
• Forrest group: Ia = 5, Ib = 47, IIa = 6 (epinephrine Ia n = 1, Ib n = 27, IIa n = 2;
combination therapy Ia n = 4, Ib n = 20, IIa n = 4)
Interventions • Primary intervention: epinephrine injection (n = 30) vs epinephrine injection and
haemoclip (n = 28)
• Medical treatment: proton pump inhibitors (PPIs) as an intravenous bolus of 80 mg,
followed by infusion of 8 mg/h for 72 hours, and after that oral PPI
• Second-look endoscopy: no (only if rebleeding suspected)
• Epinephrine volume: epinephrine diluted in physiological saline solution (1:10,000),
0.5-2 mL fractions into 4 quadrants around the ulcer. Epinephrine group mean 11 mL
(4-20 mL); epinephrine plus haemoclip 10.4 mL (4-20 mL) (no statistically significant
difference in volume)
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Grgov 2012 (Continued)
Outcomes Outcomes assessed
Rebleeding rate (initial and final), surgery rate, adequate clip placement and mortality
•Mortality criteria: mortality
•Bleeding criteria: new hematemesis or melena after the appearance of fresh blood aspira-
tion from a nasogastric probe and an increase in pulse rate over 100 per minute, decrease
in systolic blood pressure by more than 30 mm Hg and a decrease in haemoglobin of at
least 2 g/dL
• Emergency surgery
Notes Translated from Serbo-Croatian
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study authors did not explain sequence generation
Allocation concealment (selection bias) Unclear risk Study authors did not explain allocation conceal-
ment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done
Criteria: Blinding is virtually impossible in studies
on endoscopic treatment. Review authors believe
that this did not introduce significant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nomissing outcome data: 58 participants were ran-
domly assigned. All participants were accounted for
Selective reporting (reporting bias) Unclear risk The published report includes all expected out-
comes, including those that were prespecified
Kubba 1996
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 140)
• Age (years): 70 (median)
• Sex (male/female): 93/47
• Duodenal/gastric ulcer: 78/52
• Forrest group: Ia/Ib = 51, IIa = 89
Interventions Interventions
• Primary intervention: epinephrine injection (n = 70) vs epinephrine injection and
thrombin injection (n = 70)
• Medical treatment: not specified
• Second-look endoscopy: no
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Kubba 1996 (Continued)
• Epinephrine volume: 10mLmedian in epinephrine alone vs 7mLmedian in combined
therapy group
Outcomes Outcomes assessed
Rebleeding rate, surgery rate and mortality
• Mortality criteria: 30-day mortality
• Bleeding criteria: fresh hematemesis or melena plus shock or fall in haemoglobin > 2
g/dL
• Emergency surgery
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study authors did not explain sequence gener-
ation
Allocation concealment (selection bias) Low risk Quote: “Patients were randomized by opening
a sealed envelope to be administered either in-
jection with dilute epinephrine (group 1) or
epinephrine plus human thrombin (group 2).
The randomization was performed during the
endoscopy” (page 634)
Comment: probably adequate
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done
Criteria: Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors believe that this did not introduce signif-
icant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data: 140 participants
were randomly assigned (once participants/ul-
cers not meeting the inclusion criteria had been
excluded at initial endoscopy). All participants
were accounted for
Selective reporting (reporting bias) Low risk The published report includes all expected out-
comes, including those that were prespecified
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Lee 1997
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 60)
• Age (years): not specified
• Sex (male/female): not specified
• Duodenal/gastric ulcer: not specified
• Forrest group: Ia/Ib = 37, IIa = 23
Interventions Interventions
• Primary intervention: epinephrine injection vs epinephrine injection and ethanol in-
jection
• Medical treatment: not specified
• Second-look endoscopy: no
• Epinephrine volume: 17.6 mL in epinephrine group alone vs 14.7 mL in combined
therapy group
Outcomes Outcomes assessed
Rebleeding rate, surgery rate and mortality
• Mortality criteria: not specified
• Bleeding criteria: not specified
• Emergency surgery
Notes Abstract report only; bleeding ulcer participants were a subgroup of n = 60 with active
bleeding or a non-bleeding visible vessel
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study authors did not explain sequence gener-
ation (abstract)
Allocation concealment (selection bias) Unclear risk Study authors did not explain allocation con-
cealment (abstract)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done
Criteria: Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors believe that this did not introduce signif-
icant bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not possible to determine, short abstract report
Selective reporting (reporting bias) Unclear risk Study outcomes were efficacy and safety of
endoscopic treatment. All outcomes were re-
ported but not by the intervention group
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Lin 1993
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 64)
• Age (years): 59.6 (mean)
• Sex (male/female): 57/7
• Duodenal/gastric ulcer: 34/29
• Forrest group: Ia = 21 Ib = 43
Interventions Interventions
• Primary intervention: epinephrine injection (n = 32) vs epinephrine injection and
ethanol injection (n = 32)
• Medical treatment: ranitidine or cimetidine
• Second-look endoscopy: no
• Epinephrine volume: 6mL in epinephrine group vs 5.5mL in combined therapy group
Outcomes Outcomes assessed
Bleeding rate, surgery rate, hospital stay, blood transfusions and mortality
• Mortality criteria: hospital mortality
• Bleeding criteria: unstable vital signs or continued bloody stools or hematemesis
• Emergency surgery
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Two forms of injection were arranged
by a statistician who was not involved in the
study” (page 1182)
Comment: probably adequate
Allocation concealment (selection bias) Low risk Quote: “For every patient enrolled in the study,
a sealed envelope was opened before perform-
ing an endoscopic injection to decide the in-
jected solution. Two forms of injection were ar-
ranged by a statistician who was not involved
in the study” (page 1182)
Comment: probably adequate
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done
Criteria: Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors believe that this did not introduce signif-
icant bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Peptic ulcers with bleeding (oozing or spurt-
ing) were found in 100 participants. A total of
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Lin 1993 (Continued)
36 cases were excluded from the study, and it is
unclear whether they were excluded after ran-
domisation: 20 participants refused to give in-
formed consent, 8 had bleeding gastric
cancer and 8 had a bleeding tendency. 64 par-
ticipants who had actively bleeding ulcer at ini-
tial endoscopy were randomly assigned, and
all 64 participants were accounted for in each
group
Selective reporting (reporting bias) Low risk The published report includes all expected out-
comes, including those that were prespecified
Lin 1999
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 96)
• Age (years): 67.7 (mean)
• Sex (male/female): 57/7
• Duodenal/gastric ulcer: 25/37
• Forrest group: Ia = 6, Ib = 16, IIa = 42
Interventions Interventions
• Primary intervention: epinephrine injection (n = 32) vs epinephrine injection and
bipolar electrocoagulation (n = 32) (vs bipolar electrocoagulation alone = 32)
• Medical treatment: omeprazole 40 mg/6 h intravenously
• Second-look endoscopy: yes
• Epinephrine volume: 7.1 mL vs 6.8 mL
Outcomes Outcomes assessed
Bleeding rate, blood transfusions, surgery rate and mortality
• Mortality criteria: hospital mortality
• Bleeding criteria: unstable vital signs or continued bloody stools or hematemesis
• Emergency surgery
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was performed by a
statistician who was not involved in the study”
(page 716)
Comment: adequate
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Lin 1999 (Continued)
Allocation concealment (selection bias) Low risk Quote: “For every patient enrolled in the study,
a sealed envelope was opened before perform-
ing endoscopic treatment” (page 716)
Comment: adequate
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done
Criteria: Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors believe that this did not introduce signif-
icant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data: 96 randomly as-
signed, n = 1 in the epinephrine group; n = 2
in the gold probe group and n = 2 in the injec-
tion and gold probe group were excluded be-
cause no haemostasis was achieved. All other
participants were accounted for in the groups
to which they were randomly assigned
Selective reporting (reporting bias) Low risk The published report includes all expected out-
comes, including those that were prespecified
Lo 2006
Methods Randomised, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 108)
• Age (years): 63.5 (mean)
• Sex (male/female): 81/24
• Duodenal/gastric ulcer: 51/54
• Forrest group: Ia/Ib = 42, IIa = 34, IIb = 30
Interventions Interventions
• Primary intervention: epinephrine injection (n = 53) vs epinephrine injection plus
haemoclip (n = 52). Study was performed by 4 different endoscopists
• Medical treatment: pantoprazole 40 mg intravenously
• Second-look endoscopy: no
• Epinephrine volume: maximum 20 mL
Outcomes Outcomes assessed
Rebleeding rate, surgery, complications and 30-day mortality
• Mortality criteria: 30-day mortality
• Bleeding criteria: not specified
• Emergency surgery
Notes
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Lo 2006 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Page 769: “Randomization was carried out during
endoscopy by an individual not directly involved in
the study who opened the sealed and numbered en-
velopes that contained the treatment assignments,
which had been randomised with a computer pro-
gram. NB re-bleeders in the epinephrine group were
then randomised again, but the results of this second
randomised study are not added to the data from
the original groups”
Allocation concealment (selection bias) Low risk Page 769: “Randomization was carried out during
endoscopy by an individual not directly involved in
the study who opened the sealed and numbered en-
velopes that contained the treatment assignments,
which had been randomised with a computer pro-
gram”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done. Blinding is virtually impossible in studies
on endoscopic treatment. Review authors believe
that this did not introduce significant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data: 108 participants ran-
domly assigned, Three patients were excluded be-
cause of inability to obtain informed consent, gastric
malignancy or multiple bleeding sites at endoscopy
Selective reporting (reporting bias) Low risk The published report includes all expected out-
comes, including those that were prespecified
Loizou 1991
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 42)
• Age (years): 60.5 (mean)
• Sex (male/female): 31/11
• Duodenal/gastric ulcer: 22/20
• Forrest group: Ia/Ib = 8, IIa = 34
Interventions Interventions
• Primary intervention: epinephrine injection (n = 21) vs epinephrine injection and Nd:
YAG laser photocoagulation (n = 21)
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Loizou 1991 (Continued)
• Medical treatment: ranitidine 300 mg/12 h oral intake
• Second-look endoscopy: no
• Epinephrine volume: 10 mL in both groups
Outcomes Outcomes assessed
Bleeding rate, surgery rate and mortality
• Mortality criteria: 30-day mortality
• Bleeding criteria: fresh hematemesis ormelena plus shock or fall in haemoglobin despite
transfusion
• Emergency surgery
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study authors did not explain sequence gener-
ation
Comment: unclear
Allocation concealment (selection bias) Low risk Quote: “Patientswere stratified into twogroups
according to whether the visible vessel was ac-
tively bleeding at the time of endoscopy or
not and separately randomised, by opening
sealed numbered envelopes, to receive either
epinephrine injection treatment or epinephrine
injection + Nd:YAG laser photocoagulation”
(page 1101)
Comment: adequate
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done
Criteria: Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors believe that this did not introduce signif-
icant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nomissing outcome data: 42 participants were
randomly assigned at endoscopy provided they
fit the inclusion criteria. All participants were
accounted for
Selective reporting (reporting bias) Unclear risk The published report includes all expected out-
comes, including those that were prespecified
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Park 2004
Methods Randomised trial, single blinded
Participants Participant characteristics
• Number randomly assigned (n = 90)
• Age (years): 61.8 (mean)
• Sex (male/female): 76/14
• Duodenal/gastric ulcer: 18/72
• Forrest group: Ia = 18, Ib = 28, IIa = 44
Interventions Interventions
• Primary intervention: epinephrine injection (n = 45) vs epinephrine injection plus
haemoclip application or band ligation (n = 45)
• Medical treatment: ranitidine 50 mg/6 h intravenously
• Second-look endoscopy: no
• Epinephrine volume: not specified
Outcomes Outcomes assessed
Bleeding rate, surgery rate and mortality
• Mortality criteria: bleeding-related deaths
• Bleeding criteria: fresh hematemesis, instability of vital signs and/or decrease in hae-
moglobin level of more than 2 g/dL/24 h
• Emergency surgery
Notes The published report includes all expected outcomes, including those that were prespec-
ified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The allocation of patients to treatment was
by drawing sequentially numbered envelopes, each
containing a previously determined, randomly se-
lected assignment based on a table of random num-
bers” (page 174)
Comment: adequate
Allocation concealment (selection bias) Low risk Quote: “The allocation of patients to treatment was
by drawing sequentially numbered envelopes, each
containing a previously determined, randomly se-
lected assignment based on a table of random num-
bers” (page 174)
Comment: adequate
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Single blind. Quote: “A prospective, randomized,
single-blind comparative trial was conducted in a
university-affiliated academic medical center” (page
173)
Comment: It is unclear what single blinded means.
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Park 2004 (Continued)
It might be true that managing clinicians did not
know what the endoscopic treatment had been, but
this is not clearly specified in the text
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data: 90 participants were ran-
domly assigned. All participants were accounted for
in a flow diagram showing outcomes for all. “Peptic
ulcer with either an actively bleeding vessel (spurt-
ing or oozing) or a non-bleeding visible vessel was
found in 123 patients. Thirty-three were excluded
(before randomisation) because of inability to obtain
informed consent, bleeding diathesis, gastric malig-
nancy” (study report, page 175)
Selective reporting (reporting bias) Low risk The published report includes all expected out-
comes, including those that were prespecified
Pescatore 2002
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 135)
• Age (years): 68.7 (median)
• Sex (male/female): 90/45
• Duodenal/gastric ulcer: 88/47
• Forrest group: Ia = 15, Ib = 47, IIa = 51, IIb = 22
Interventions Interventions
• Primary intervention: epinephrine injection (n = 70) vs epinephrine injection plus
fibrin glue (n = 65)
• Medical treatment: not specified
• Second-look endoscopy: yes
• Epinephrine volume: 10.3 mL in epinephrine group vs 7.5 mL in combined therapy
Outcomes Outcomes assessed
Bleeding rate, surgery rate, blood transfusion and mortality
• Mortality criteria: 30-day mortality
• Bleeding criteria: fresh hematemesis ormelena plus shock or fall in haemoglobin despite
transfusion
• Emergency surgery
Notes The published report includes all expected outcomes, including those that were prespec-
ified
Risk of bias
Bias Authors’ judgement Support for judgement
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Pescatore 2002 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performedwithin
each center by using a computer-generated ran-
domization list and sealed envelopes” (page
349)
Comment: adequate
Allocation concealment (selection bias) Low risk Quote: “Randomization was performedwithin
each center by using a computer-generated ran-
domization list and sealed envelopes” (page
349)
Comment: adequate
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done
Criteria: Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors believe that this did not introduce signif-
icant bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No missing outcome data: 135 participants
were randomly assigned. Unclear whether the
following participants were excluded after ran-
domisation: “Patients were excluded because of
endoscopically uncontrollable bleeding; these
patients underwent immediate surgery. Three
of the latter patients had large bleeding vessels
on the posterior aspect of the duodenal bulb,
whereas 1 patient bled from an aorto-duode-
nal fistula. Two further patients were excluded
because of a suspicion that the bleeding gastric
ulcer was neoplastic (later confirmed by histol-
ogy)” (study report, page 350)
Unclear whether all randomly assigned partic-
ipants were accounted for, as some outcomes
are reported as percentages
Selective reporting (reporting bias) Low risk The published report includes all expected out-
comes, including those that were prespecified
Sollano 1991
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 83)
• Age (years): not specified
• Sex (male/female): not specified
• Duodenal/gastric ulcer: 29/29
• Forrest group: Ia = 6, Ib = 35, IIa = 20
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Sollano 1991 (Continued)
Interventions Interventions
• Primary intervention: epinephrine injection (n = 32) vs epinephrine injection and
ethoxy sclerol (n = 29) (vs heater probe only n = 22)
• Medical treatment: not specified
• Second-look endoscopy: yes
• Epinephrine volume: 8.6 mL in epinephrine alone vs 11 mL in combined therapy
Outcomes Outcomes assessed
Bleeding rate, surgery rate and mortality
• Mortality criteria: not specified
• Bleeding criteria: recurrence of hematemesis, melena or anaemia
• Emergency surgery (after rebleeding)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: did not explain sequence genera-
tion
Allocation concealment (selection bias) Unclear risk Comment: did not explain allocation conceal-
ment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done
Criteria: Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors believe that this did not introduce signif-
icant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data: 83 were ran-
domly assigned to epinephrine injection vs
epinephrine injection and haemoclip applica-
tion or band ligation
Selective reporting (reporting bias) Low risk The published report includes all expected out-
comes, including those that were prespecified
Villanueva 1993
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 63)
• Age (years): 62 (mean)
• Sex (male/female): 43/20
• Duodenal/gastric ulcer: 31/30
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Villanueva 1993 (Continued)
• Forrest group: Ia = 1, Ib = 22, IIa = 40
Interventions Interventions
• Primary intervention: epinephrine injection (n = 30) vs epinephrine injection and
polidocanol injection (n = 33)
• Medical treatment: ranitidine 50 mg/6 h intravenously
• Second-look endoscopy: yes
• Epinephrine volume: Both groups received epinephrine in equal amounts. Those in
group B also received polidocanol; accordingly, the total volume injected was greater (12
mL in epinephrine alone vs 15.2 mL in combined therapy-group B-)
Outcomes Outcomes assessed
Bleeding rate, surgery rate, blood transfusions and mortality
• Mortality criteria: hospital mortality
•Bleeding criteria: fresh hematemesis ormelena plus hypovolaemia or fall in haemoglobin
requiring transfusion
• Emergency surgery
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Comment: adequate
Allocation concealment (selection bias) Low risk An opaque sealed envelope
Comment: adequate
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done: Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors believe that this did not introduce signif-
icant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nomissing outcome data: 63 participants were
randomly assigned. 3 additional participants
were excluded, as they were found not to fit
with the inclusion criteria on endoscopy (rea-
sons given). Outcomes were reported for all
participants who remained in the study
Selective reporting (reporting bias) Unclear risk The published report includes all expected out-
comes, including those that were prespecified
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Villanueva 1996
Methods Randomised trial, not double blinded
Participants Participant characteristics
• Number randomly assigned (n = 78)
• Age (years): not specified
• Sex (male/female): not specified
• Duodenal/gastric ulcer: not specified
• Forrest group: Ia/Ib = 25, IIa = 53
Interventions Interventions
• Primary intervention: epinephrine injection vs epinephrine injection and polidocanol
injection
• Medical treatment: ranitidine
• Second-look endoscopy: no
• Epinephrine volume: not specified
Outcomes Outcomes assessed
Bleeding rate, surgery rate and mortality
• Mortality criteria: hospital mortality
• Bleeding criteria: not specified
• Emergency surgery
Notes Abstract report only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study authors did not explain sequence gener-
ation (abstract)
Allocation concealment (selection bias) Unclear risk Study authors did not explain (abstract)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not done: Blinding is virtually impossible in
studies on endoscopic treatment. Review au-
thors that this did not introduce significant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for in the
groups to which they were randomly assigned
Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Buffoli 2001 Not randomised
Chittmittrapap 2010 Non-randomised (retrospective) study
Chua 2001 Not randomised
Chung 1990 Preliminary results published later in another article
Chung 1992 Preliminary results published later in another article
Chung 1997a Preliminary results published later in another article
De Goede 1998 Preliminary results published later in another article
Dedeu 2003 Does not specify number of participants in each group
We contacted the author but did not receive an answer
Ell 2002 Does not specify number of participants in each group
It was not possible to contact this study author to clarify the results. The study was published only as an
abstract, and no contact address was provided
Gevers 2002 Combined epinephrine plus polidocanol in both groups
Grgov 2013 Randomised,(n = 70) but compared (n = 34) participants with endoscopic haemoclip therapy versus (n = 36)
participants with epinephrine injection plus endoscopic haemoclip therapy Compared haemoclip with and
without epinephrine, does not fit inclusion criteria. Serbo-Croatian
Karaman 2011 Compares APC or heater probe. Epinephrine injection (5-6 mL, 1:10,000 dilution) was applied around the
ulcer in all participants before both of these 2 methods were applied. Does not fit our inclusion criteria
(epinephrine vs epinephrine plus second method)
Lecleire 2009 Mallory Weiss not in our inclusion criteria, not a comparison of epinephrine vs epinephrine plus second
method
Ljubicic 2012 Compares small volume epinephrine vs large volume epinephrine vs haemoclip alone
Male 1999 Preliminary results published later in another article
Pescatore 1999 Preliminary results published later in another article
Sabat 1998 No definition of further clinically significant bleeding was established, only endoscopic rebleeding. The aim
of the study was directed to endoscopic signs, not to clinical rebleeding
Taghavi 2009 Randomised, but not epinephrine vs epinephrine plus second method (i.e. compared epinephrine injection
plus argon plasma coagulation vs epinephrine injection plus haemoclips)
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Tsoi 2009 Review article, not trial report
Wehrmann 1994 Study was excluded because primary endpoint was not achieved. Included studies must define clinically
relevant rebleeding (confirmed by endoscopy), but in this study, investigators considered only endoscopic
rebleeding. Results did not allow detection of which participants presented with clinical rebleeding
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D A T A A N D A N A L Y S E S
Comparison 1. Epinephrine versus epinephrine and any second endoscopic method
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Initial failure of haemostasis
(persistent bleeding)
14 1380 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.42, 1.40]
2 Recurrent bleeding only
(bleeding after initial
haemostasis)
14 1333 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.35, 0.81]
3 Recurrent and persistent
bleeding overall rates with
or without second-look
endoscopy
19 1926 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.43, 0.76]
4 Recurrent and persistent
bleeding and second-look
endoscopy
19 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Confirmed by second-look
endoscopy
10 1203 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.64, 1.06]
4.2 Without second-look
endoscopy
9 720 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.21, 0.48]
5 Surgery rate 18 1841 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.50, 0.93]
6 Mortality rate 18 1841 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.39, 1.06]
7 Adverse effects of endoscopy
therapy
12 1281 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.40, 3.96]
8 Recurrent and persistent
bleeding according to type of
haemorrhage
13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Forrest Ia-Ib (spurting or
oozing haemorrhage)
13 1019 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.49, 0.88]
8.2 Forrest IIa (visible vessel) 9 448 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.47, 1.99]
8.3 Forrrest IIb (adherent clot) 2 30 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.22, 2.60]
Comparison 2. Epinephrine plus epinephrine and a second injected agent
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrent and persistent
bleeding
11 1135 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.53, 1.04]
2 Surgery rate 10 1050 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.59, 1.21]
3 Mortality rate 10 1050 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.25, 1.00]
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Comparison 3. Epinephrine versus epinephrine and mechanical endoscopic methods
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrrent and persistent
bleeding
5 415 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.18, 0.55]
2 Surgery rate 5 415 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.06, 0.62]
3 Mortality rate 5 415 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.19, 2.71]
Comparison 4. Epinephrine plus epinephrine and thermal methods
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrent and persistent
bleeding
3 376 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.30, 0.78]
2 Surgery rate 3 376 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.21, 0.95]
3 Mortality rate 3 376 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.37, 2.26]
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Analysis 1.1. Comparison 1 Epinephrine versus epinephrine and any second endoscopic method, Outcome
1 Initial failure of haemostasis (persistent bleeding).
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 1 Epinephrine versus epinephrine and any second endoscopic method
Outcome: 1 Initial failure of haemostasis (persistent bleeding)
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sollano 1991 0/29 0/32 Not estimable
Loizou 1991 0/21 2/21 4.0 % 0.20 [ 0.01, 3.93 ]
Lo 2006 1/52 4/53 7.7 % 0.25 [ 0.03, 2.20 ]
Chung 1997 1/136 3/134 7.1 % 0.33 [ 0.03, 3.12 ]
Lin 1993 0/32 1/32 3.6 % 0.33 [ 0.01, 7.89 ]
Chung 1999 1/42 2/41 6.4 % 0.49 [ 0.05, 5.18 ]
Chung 1993 3/98 6/98 19.5 % 0.50 [ 0.13, 1.94 ]
Grgov 2012 1/28 2/30 6.5 % 0.54 [ 0.05, 5.59 ]
Villanueva 1993 1/33 1/30 4.8 % 0.91 [ 0.06, 13.90 ]
Park 2004 1/45 1/45 4.8 % 1.00 [ 0.06, 15.50 ]
Balanzo 1990 3/32 2/32 12.1 % 1.50 [ 0.27, 8.38 ]
Lin 1999 2/32 1/32 6.5 % 2.00 [ 0.19, 20.97 ]
Chung 1996 4/79 2/81 12.9 % 2.05 [ 0.39, 10.88 ]
Lee 1997 2/30 0/30 4.0 % 5.00 [ 0.25, 99.95 ]
Total (95% CI) 689 691 100.0 % 0.77 [ 0.42, 1.40 ]
Total events: 20 (Combined therapy), 27 (Epinephrine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.32, df = 12 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Combined therapy Epinephrine alone
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Analysis 1.2. Comparison 1 Epinephrine versus epinephrine and any second endoscopic method, Outcome
2 Recurrent bleeding only (bleeding after initial haemostasis).
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 1 Epinephrine versus epinephrine and any second endoscopic method
Outcome: 2 Recurrent bleeding only (bleeding after initial haemostasis)
Study or subgroup Combined therapy Epineprhine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Grgov 2012 1/27 8/28 3.6 % 0.13 [ 0.02, 0.97 ]
Lo 2006 2/51 11/49 5.8 % 0.17 [ 0.04, 0.75 ]
Lin 1999 2/30 11/31 6.0 % 0.19 [ 0.05, 0.78 ]
Lee 1997 2/28 10/30 6.0 % 0.21 [ 0.05, 0.89 ]
Sollano 1991 0/29 2/32 1.8 % 0.22 [ 0.01, 4.40 ]
Park 2004 2/44 9/44 5.7 % 0.22 [ 0.05, 0.97 ]
Lin 1993 5/32 11/31 9.9 % 0.44 [ 0.17, 1.12 ]
Balanzo 1990 2/29 4/30 5.0 % 0.52 [ 0.10, 2.61 ]
Chung 1997 14/135 25/131 13.8 % 0.54 [ 0.30, 1.00 ]
Chung 1999 4/41 6/39 7.6 % 0.63 [ 0.19, 2.08 ]
Loizou 1991 3/21 3/19 5.7 % 0.90 [ 0.21, 3.96 ]
Chung 1996 12/75 11/79 12.0 % 1.15 [ 0.54, 2.44 ]
Chung 1993 9/95 7/92 9.8 % 1.25 [ 0.48, 3.20 ]
Villanueva 1993 7/32 3/29 7.1 % 2.11 [ 0.60, 7.42 ]
Total (95% CI) 669 664 100.0 % 0.53 [ 0.35, 0.81 ]
Total events: 65 (Combined therapy), 121 (Epineprhine alone)
Heterogeneity: Tau2 = 0.24; Chi2 = 21.92, df = 13 (P = 0.06); I2 =41%
Test for overall effect: Z = 2.93 (P = 0.0033)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Combined therapy Epinephrine alone
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Analysis 1.3. Comparison 1 Epinephrine versus epinephrine and any second endoscopic method, Outcome
3 Recurrent and persistent bleeding overall rates with or without second-look endoscopy.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 1 Epinephrine versus epinephrine and any second endoscopic method
Outcome: 3 Recurrent and persistent bleeding overall rates with or without second-look endoscopy
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lo 2006 3/52 15/53 4.2 % 0.20 [ 0.06, 0.66 ]
Grgov 2012 2/28 10/30 3.1 % 0.21 [ 0.05, 0.89 ]
Kubba 1996 3/70 14/70 4.1 % 0.21 [ 0.06, 0.71 ]
Villanueva 1996 2/42 7/37 2.9 % 0.25 [ 0.06, 1.14 ]
Garrido 2002 3/40 12/45 4.1 % 0.28 [ 0.09, 0.93 ]
Park 2004 3/45 10/45 4.0 % 0.30 [ 0.09, 1.02 ]
Lin 1999 4/32 12/32 5.1 % 0.33 [ 0.12, 0.92 ]
Lee 1997 4/30 10/30 4.9 % 0.40 [ 0.14, 1.14 ]
Lin 1993 5/32 12/32 5.8 % 0.42 [ 0.17, 1.05 ]
Chung 1997 15/136 28/134 9.2 % 0.53 [ 0.30, 0.94 ]
Loizou 1991 3/21 5/21 3.6 % 0.60 [ 0.16, 2.20 ]
Chung 1999 5/42 8/41 5.0 % 0.61 [ 0.22, 1.71 ]
Balanzo 1990 5/32 6/32 4.7 % 0.83 [ 0.28, 2.46 ]
Pescatore 2002 14/65 17/70 8.7 % 0.89 [ 0.48, 1.65 ]
Choudari 1994 7/52 8/55 5.7 % 0.93 [ 0.36, 2.37 ]
Chung 1993 21/98 22/98 9.9 % 0.95 [ 0.56, 1.62 ]
Sollano 1991 2/29 2/32 1.9 % 1.10 [ 0.17, 7.34 ]
Chung 1996 16/79 14/81 8.4 % 1.17 [ 0.61, 2.24 ]
Villanueva 1993 8/33 4/30 4.6 % 1.82 [ 0.61, 5.43 ]
Total (95% CI) 958 968 100.0 % 0.57 [ 0.43, 0.76 ]
Total events: 125 (Combined therapy), 216 (Epinephrine alone)
Heterogeneity: Tau2 = 0.14; Chi2 = 29.11, df = 18 (P = 0.05); I2 =38%
Test for overall effect: Z = 3.85 (P = 0.00012)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Epinephrine versus epinephrine and any second endoscopic method, Outcome
4 Recurrent and persistent bleeding and second-look endoscopy.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 1 Epinephrine versus epinephrine and any second endoscopic method
Outcome: 4 Recurrent and persistent bleeding and second-look endoscopy
Study or subgroup Combined therapy Epinephrine alonel Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Confirmed by second-look endoscopy
Lin 1999 4/32 12/32 6.0 % 0.33 [ 0.12, 0.92 ]
Chung 1997 15/136 28/134 17.8 % 0.53 [ 0.30, 0.94 ]
Chung 1999 5/42 8/41 5.8 % 0.61 [ 0.22, 1.71 ]
Balanzo 1990 5/32 6/32 5.3 % 0.83 [ 0.28, 2.46 ]
Pescatore 2002 14/65 17/70 15.6 % 0.89 [ 0.48, 1.65 ]
Choudari 1994 7/52 8/55 7.0 % 0.93 [ 0.36, 2.37 ]
Chung 1993 21/98 22/98 21.2 % 0.95 [ 0.56, 1.62 ]
Sollano 1991 2/29 2/32 1.8 % 1.10 [ 0.17, 7.34 ]
Chung 1996 16/79 14/81 14.4 % 1.17 [ 0.61, 2.24 ]
Villanueva 1993 8/33 4/30 5.2 % 1.82 [ 0.61, 5.43 ]
Subtotal (95% CI) 598 605 100.0 % 0.82 [ 0.64, 1.06 ]
Total events: 97 (Combined therapy), 121 (Epinephrine alonel)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.28, df = 9 (P = 0.41); I2 =3%
Test for overall effect: Z = 1.53 (P = 0.13)
2 Without second-look endoscopy
Grgov 2012 1/27 8/28 4.0 % 0.13 [ 0.02, 0.97 ]
Lo 2006 3/52 15/53 11.7 % 0.20 [ 0.06, 0.66 ]
Kubba 1996 3/70 14/70 11.3 % 0.21 [ 0.06, 0.71 ]
Villanueva 1996 2/42 7/37 7.2 % 0.25 [ 0.06, 1.14 ]
Park 2004 3/45 10/45 10.9 % 0.30 [ 0.09, 1.02 ]
Garrido 2002 3/40 10/45 11.0 % 0.34 [ 0.10, 1.14 ]
Lee 1997 4/30 10/30 15.0 % 0.40 [ 0.14, 1.14 ]
Lin 1993 5/32 12/32 19.2 % 0.42 [ 0.17, 1.05 ]
Loizou 1991 3/21 5/21 9.7 % 0.60 [ 0.16, 2.20 ]
Subtotal (95% CI) 359 361 100.0 % 0.32 [ 0.21, 0.48 ]
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(. . . Continued)
Study or subgroup Combined therapy Epinephrine alonel Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 27 (Combined therapy), 91 (Epinephrine alonel)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.36, df = 8 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 5.57 (P < 0.00001)
Test for subgroup differences: Chi2 = 15.37, df = 1 (P = 0.00), I2 =93%
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Analysis 1.5. Comparison 1 Epinephrine versus epinephrine and any second endoscopic method, Outcome
5 Surgery rate.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 1 Epinephrine versus epinephrine and any second endoscopic method
Outcome: 5 Surgery rate
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lo 2006 0/52 5/53 1.2 % 0.09 [ 0.01, 1.63 ]
Loizou 1991 0/21 3/21 1.1 % 0.14 [ 0.01, 2.61 ]
Chung 1999 1/42 6/41 2.3 % 0.16 [ 0.02, 1.29 ]
Lin 1999 1/32 5/32 2.2 % 0.20 [ 0.02, 1.62 ]
Grgov 2012 0/28 2/30 1.1 % 0.21 [ 0.01, 4.27 ]
Villanueva 1996 1/42 3/37 2.0 % 0.29 [ 0.03, 2.70 ]
Park 2004 0/45 1/45 1.0 % 0.33 [ 0.01, 7.97 ]
Sollano 1991 0/29 1/32 1.0 % 0.37 [ 0.02, 8.66 ]
Lin 1993 2/32 4/32 3.7 % 0.50 [ 0.10, 2.54 ]
Chung 1997 8/136 14/134 13.9 % 0.56 [ 0.24, 1.30 ]
Kubba 1996 3/70 5/70 5.0 % 0.60 [ 0.15, 2.41 ]
Pescatore 2002 4/65 7/70 6.9 % 0.62 [ 0.19, 2.01 ]
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(. . . Continued)
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chung 1996 9/79 12/81 14.9 % 0.77 [ 0.34, 1.72 ]
Chung 1993 14/98 16/98 22.2 % 0.88 [ 0.45, 1.69 ]
Choudari 1994 4/52 4/55 5.4 % 1.06 [ 0.28, 4.01 ]
Villanueva 1993 5/33 4/30 6.5 % 1.14 [ 0.34, 3.84 ]
Balanzo 1990 5/32 4/32 6.5 % 1.25 [ 0.37, 4.23 ]
Lee 1997 3/30 2/30 3.3 % 1.50 [ 0.27, 8.34 ]
Total (95% CI) 918 923 100.0 % 0.68 [ 0.50, 0.93 ]
Total events: 60 (Combined therapy), 98 (Epinephrine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.82, df = 17 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Epinephrine versus epinephrine and any second endoscopic method, Outcome
6 Mortality rate.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 1 Epinephrine versus epinephrine and any second endoscopic method
Outcome: 6 Mortality rate
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Balanzo 1990 0/32 0/32 Not estimable
Loizou 1991 0/21 0/21 Not estimable
Kubba 1996 0/70 7/70 3.2 % 0.07 [ 0.00, 1.15 ]
Lee 1997 0/30 3/30 3.0 % 0.14 [ 0.01, 2.65 ]
Villanueva 1996 0/42 2/37 2.8 % 0.18 [ 0.01, 3.57 ]
Lin 1999 1/32 3/32 5.3 % 0.33 [ 0.04, 3.04 ]
Park 2004 0/45 1/45 2.5 % 0.33 [ 0.01, 7.97 ]
Choudari 1994 0/52 1/55 2.5 % 0.35 [ 0.01, 8.46 ]
Sollano 1991 0/29 1/32 2.6 % 0.37 [ 0.02, 8.66 ]
Chung 1993 4/98 9/98 19.6 % 0.44 [ 0.14, 1.40 ]
Villanueva 1993 1/33 2/30 4.6 % 0.45 [ 0.04, 4.76 ]
Chung 1996 2/79 3/81 8.3 % 0.68 [ 0.12, 3.98 ]
Chung 1999 1/42 1/41 3.4 % 0.98 [ 0.06, 15.09 ]
Grgov 2012 1/28 1/30 3.5 % 1.07 [ 0.07, 16.32 ]
Pescatore 2002 2/65 2/70 6.9 % 1.08 [ 0.16, 7.42 ]
Chung 1997 8/136 7/134 26.4 % 1.13 [ 0.42, 3.02 ]
Lo 2006 1/52 0/53 2.5 % 3.06 [ 0.13, 73.36 ]
Lin 1993 2/32 0/32 2.9 % 5.00 [ 0.25, 100.20 ]
Total (95% CI) 918 923 100.0 % 0.64 [ 0.39, 1.06 ]
Total events: 23 (Combined therapy), 43 (Epinephrine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 10.06, df = 15 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Epinephrine versus epinephrine and any second endoscopic method, Outcome
7 Adverse effects of endoscopy therapy.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 1 Epinephrine versus epinephrine and any second endoscopic method
Outcome: 7 Adverse effects of endoscopy therapy
Study or subgroup Combined treatment Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lin 1999 0/32 0/32 Not estimable
Kubba 1996 0/70 0/70 Not estimable
Grgov 2012 0/30 0/28 Not estimable
Lo 2006 0/52 0/53 Not estimable
Lin 1993 0/32 0/32 Not estimable
Chung 1999 0/42 3/41 15.4 % 0.14 [ 0.01, 2.62 ]
Loizou 1991 0/21 1/21 13.4 % 0.33 [ 0.01, 7.74 ]
Pescatore 2002 1/65 1/70 17.5 % 1.08 [ 0.07, 16.87 ]
Villanueva 1993 1/33 0/30 13.2 % 2.74 [ 0.12, 64.69 ]
Chung 1993 1/98 0/98 13.0 % 3.00 [ 0.12, 72.75 ]
Sollano 1991 1/29 0/32 13.2 % 3.30 [ 0.14, 77.95 ]
Chung 1997 2/136 0/134 14.4 % 4.93 [ 0.24, 101.67 ]
Total (95% CI) 640 641 100.0 % 1.25 [ 0.40, 3.96 ]
Total events: 6 (Combined treatment), 5 (Epinephrine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.55, df = 6 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Epinephrine versus epinephrine and any second endoscopic method, Outcome
8 Recurrent and persistent bleeding according to type of haemorrhage.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 1 Epinephrine versus epinephrine and any second endoscopic method
Outcome: 8 Recurrent and persistent bleeding according to type of haemorrhage
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Forrest Ia-Ib (spurting or oozing haemorrhage)
Kubba 1996 2/27 9/24 3.8 % 0.20 [ 0.05, 0.83 ]
Garrido 2002 2/10 10/15 4.6 % 0.30 [ 0.08, 1.09 ]
Park 2004 2/23 6/21 3.6 % 0.30 [ 0.07, 1.35 ]
Chung 1999 3/21 5/14 4.8 % 0.40 [ 0.11, 1.41 ]
Lin 1993 5/32 12/32 8.4 % 0.42 [ 0.17, 1.05 ]
Chung 1997 15/136 28/134 17.1 % 0.53 [ 0.30, 0.94 ]
Pescatore 2002 5/30 10/32 8.0 % 0.53 [ 0.21, 1.38 ]
Choudari 1994 6/28 7/29 7.8 % 0.89 [ 0.34, 2.32 ]
Chung 1993 21/98 22/98 19.3 % 0.95 [ 0.56, 1.62 ]
Villanueva 1993 3/13 2/10 3.2 % 1.15 [ 0.24, 5.65 ]
Chung 1996 16/79 14/81 14.7 % 1.17 [ 0.61, 2.24 ]
Balanzo 1990 2/11 2/13 2.5 % 1.18 [ 0.20, 7.06 ]
Loizou 1991 2/5 1/3 2.2 % 1.20 [ 0.17, 8.24 ]
Subtotal (95% CI) 513 506 100.0 % 0.66 [ 0.49, 0.88 ]
Total events: 84 (Combined therapy), 128 (Epinephrine alone)
Heterogeneity: Tau2 = 0.04; Chi2 = 14.11, df = 12 (P = 0.29); I2 =15%
Test for overall effect: Z = 2.83 (P = 0.0046)
2 Forrest IIa (visible vessel)
Park 2004 0/21 3/23 5.3 % 0.16 [ 0.01, 2.85 ]
Kubba 1996 1/43 5/46 9.1 % 0.21 [ 0.03, 1.76 ]
Loizou 1991 1/16 4/16 9.2 % 0.25 [ 0.03, 2.00 ]
Garrido 2002 1/26 2/26 7.7 % 0.50 [ 0.05, 5.18 ]
Balanzo 1990 3/21 4/19 16.4 % 0.68 [ 0.17, 2.65 ]
Choudari 1994 1/24 1/28 6.0 % 1.17 [ 0.08, 17.67 ]
Pescatore 2002 6/24 3/27 17.7 % 2.25 [ 0.63, 8.03 ]
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(. . . Continued)
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Villanueva 1993 5/20 2/20 14.4 % 2.50 [ 0.55, 11.41 ]
Chung 1999 5/21 2/27 14.2 % 3.21 [ 0.69, 14.96 ]
Subtotal (95% CI) 216 232 100.0 % 0.97 [ 0.47, 1.99 ]
Total events: 23 (Combined therapy), 26 (Epinephrine alone)
Heterogeneity: Tau2 = 0.34; Chi2 = 11.29, df = 8 (P = 0.19); I2 =29%
Test for overall effect: Z = 0.09 (P = 0.93)
3 Forrrest IIb (adherent clot)
Garrido 2002 0/4 0/4 Not estimable
Pescatore 2002 3/11 4/11 100.0 % 0.75 [ 0.22, 2.60 ]
Subtotal (95% CI) 15 15 100.0 % 0.75 [ 0.22, 2.60 ]
Total events: 3 (Combined therapy), 4 (Epinephrine alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 0.96, df = 2 (P = 0.62), I2 =0.0%
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Analysis 2.1. Comparison 2 Epinephrine plus epinephrine and a second injected agent, Outcome 1
Recurrent and persistent bleeding.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 2 Epinephrine plus epinephrine and a second injected agent
Outcome: 1 Recurrent and persistent bleeding
Study or subgroup
Combined
epinephrine Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kubba 1996 3/70 14/70 6.2 % 0.21 [ 0.06, 0.71 ]
Garrido 2002 3/40 12/45 6.3 % 0.28 [ 0.09, 0.93 ]
Lee 1997 4/30 10/30 7.7 % 0.40 [ 0.14, 1.14 ]
Lin 1993 5/32 12/32 9.1 % 0.42 [ 0.17, 1.05 ]
Balanzo 1990 5/32 6/32 7.3 % 0.83 [ 0.28, 2.46 ]
Pescatore 2002 14/65 17/70 14.3 % 0.89 [ 0.48, 1.65 ]
Choudari 1994 7/52 8/55 8.9 % 0.93 [ 0.36, 2.37 ]
Chung 1993 21/98 22/98 16.5 % 0.95 [ 0.56, 1.62 ]
Sollano 1991 2/29 2/32 2.9 % 1.10 [ 0.17, 7.34 ]
Chung 1996 16/79 14/81 13.7 % 1.17 [ 0.61, 2.24 ]
Villanueva 1993 8/33 4/30 7.2 % 1.82 [ 0.61, 5.43 ]
Total (95% CI) 560 575 100.0 % 0.74 [ 0.53, 1.04 ]
Total events: 88 (Combined epinephrine), 121 (Epinephrine alone)
Heterogeneity: Tau2 = 0.11; Chi2 = 15.60, df = 10 (P = 0.11); I2 =36%
Test for overall effect: Z = 1.74 (P = 0.081)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Epinephrine plus epinephrine and a second injected agent, Outcome 2 Surgery
rate.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 2 Epinephrine plus epinephrine and a second injected agent
Outcome: 2 Surgery rate
Study or subgroup
Combined
epinephrine Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sollano 1991 0/29 1/32 1.3 % 0.37 [ 0.02, 8.66 ]
Lin 1993 2/32 4/32 4.9 % 0.50 [ 0.10, 2.54 ]
Kubba 1996 3/70 5/70 6.6 % 0.60 [ 0.15, 2.41 ]
Pescatore 2002 4/65 7/70 9.2 % 0.62 [ 0.19, 2.01 ]
Chung 1996 9/79 12/81 19.7 % 0.77 [ 0.34, 1.72 ]
Chung 1993 14/98 16/98 29.4 % 0.88 [ 0.45, 1.69 ]
Choudari 1994 4/52 4/55 7.2 % 1.06 [ 0.28, 4.01 ]
Villanueva 1993 5/33 4/30 8.7 % 1.14 [ 0.34, 3.84 ]
Balanzo 1990 5/32 4/32 8.6 % 1.25 [ 0.37, 4.23 ]
Lee 1997 3/30 2/30 4.4 % 1.50 [ 0.27, 8.34 ]
Total (95% CI) 520 530 100.0 % 0.85 [ 0.59, 1.21 ]
Total events: 49 (Combined epinephrine), 59 (Epinephrine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.40, df = 9 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Epinephrine plus epinephrine and a second injected agent, Outcome 3
Mortality rate.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 2 Epinephrine plus epinephrine and a second injected agent
Outcome: 3 Mortality rate
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Balanzo 1990 0/32 0/32 Not estimable
Kubba 1996 0/70 7/70 5.9 % 0.07 [ 0.00, 1.15 ]
Lee 1997 0/30 3/30 5.6 % 0.14 [ 0.01, 2.65 ]
Choudari 1994 0/52 1/55 4.7 % 0.35 [ 0.01, 8.46 ]
Sollano 1991 0/29 1/32 4.8 % 0.37 [ 0.02, 8.66 ]
Chung 1993 4/98 9/98 36.6 % 0.44 [ 0.14, 1.40 ]
Villanueva 1993 1/33 2/30 8.7 % 0.45 [ 0.04, 4.76 ]
Chung 1996 2/79 3/81 15.4 % 0.68 [ 0.12, 3.98 ]
Pescatore 2002 2/65 2/70 12.9 % 1.08 [ 0.16, 7.42 ]
Lin 1993 2/32 0/32 5.3 % 5.00 [ 0.25, 100.20 ]
Total (95% CI) 520 530 100.0 % 0.50 [ 0.25, 1.00 ]
Total events: 11 (Combined therapy), 28 (Epinephrine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.85, df = 8 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Epinephrine versus epinephrine and mechanical endoscopic methods, Outcome
1 Recurrrent and persistent bleeding.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 3 Epinephrine versus epinephrine and mechanical endoscopic methods
Outcome: 1 Recurrrent and persistent bleeding
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lo 2006 3/52 15/53 22.1 % 0.20 [ 0.06, 0.66 ]
Grgov 2012 2/28 10/30 15.0 % 0.21 [ 0.05, 0.89 ]
Villanueva 1996 2/42 7/37 13.5 % 0.25 [ 0.06, 1.14 ]
Park 2004 3/45 10/45 20.5 % 0.30 [ 0.09, 1.02 ]
Chung 1999 5/42 8/41 28.9 % 0.61 [ 0.22, 1.71 ]
Total (95% CI) 209 206 100.0 % 0.31 [ 0.18, 0.55 ]
Total events: 15 (Combined therapy), 50 (Epinephrine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.51, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 4.10 (P = 0.000041)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Epinephrine versus epinephrine and mechanical endoscopic methods, Outcome
2 Surgery rate.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 3 Epinephrine versus epinephrine and mechanical endoscopic methods
Outcome: 2 Surgery rate
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lo 2006 0/52 5/53 15.8 % 0.09 [ 0.01, 1.63 ]
Chung 1999 1/42 6/41 30.3 % 0.16 [ 0.02, 1.29 ]
Grgov 2012 0/28 2/30 14.5 % 0.21 [ 0.01, 4.27 ]
Villanueva 1996 1/42 3/37 26.4 % 0.29 [ 0.03, 2.70 ]
Park 2004 0/45 1/45 12.9 % 0.33 [ 0.01, 7.97 ]
Total (95% CI) 209 206 100.0 % 0.20 [ 0.06, 0.62 ]
Total events: 2 (Combined therapy), 17 (Epinephrine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 4 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0055)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Epinephrine versus epinephrine and mechanical endoscopic methods, Outcome
3 Mortality rate.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 3 Epinephrine versus epinephrine and mechanical endoscopic methods
Outcome: 3 Mortality rate
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Villanueva 1996 0/42 2/37 19.2 % 0.18 [ 0.01, 3.57 ]
Park 2004 0/45 1/45 17.2 % 0.33 [ 0.01, 7.97 ]
Chung 1999 1/42 1/41 23.1 % 0.98 [ 0.06, 15.09 ]
Grgov 2012 1/28 1/30 23.4 % 1.07 [ 0.07, 16.32 ]
Lo 2006 1/52 0/53 17.2 % 3.06 [ 0.13, 73.36 ]
Total (95% CI) 209 206 100.0 % 0.73 [ 0.19, 2.71 ]
Total events: 3 (Combined therapy), 5 (Epinephrine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.00, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Combination therapy Epineprhine alone
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Analysis 4.1. Comparison 4 Epinephrine plus epinephrine and thermal methods, Outcome 1 Recurrent and
persistent bleeding.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 4 Epinephrine plus epinephrine and thermal methods
Outcome: 1 Recurrent and persistent bleeding
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lin 1999 4/32 12/32 21.2 % 0.33 [ 0.12, 0.92 ]
Chung 1997 15/136 28/134 65.7 % 0.53 [ 0.30, 0.94 ]
Loizou 1991 3/21 5/21 13.1 % 0.60 [ 0.16, 2.20 ]
Total (95% CI) 189 187 100.0 % 0.49 [ 0.30, 0.78 ]
Total events: 22 (Combined therapy), 45 (Epinephrine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Combination therapy Epinephrine alone
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Analysis 4.2. Comparison 4 Epinephrine plus epinephrine and thermal methods, Outcome 2 Surgery rate.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 4 Epinephrine plus epinephrine and thermal methods
Outcome: 2 Surgery rate
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Loizou 1991 0/21 3/21 6.7 % 0.14 [ 0.01, 2.61 ]
Lin 1999 1/32 5/32 12.9 % 0.20 [ 0.02, 1.62 ]
Chung 1997 8/136 14/134 80.5 % 0.56 [ 0.24, 1.30 ]
Total (95% CI) 189 187 100.0 % 0.45 [ 0.21, 0.95 ]
Total events: 9 (Combined therapy), 22 (Epinephrine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.49, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Combination therapy Epineprhine alone
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Analysis 4.3. Comparison 4 Epinephrine plus epinephrine and thermal methods, Outcome 3 Mortality rate.
Review: Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers
Comparison: 4 Epinephrine plus epinephrine and thermal methods
Outcome: 3 Mortality rate
Study or subgroup Combined therapy Epinephrine alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Loizou 1991 0/21 0/21 Not estimable
Lin 1999 1/32 3/32 16.6 % 0.33 [ 0.04, 3.04 ]
Chung 1997 8/136 7/134 83.4 % 1.13 [ 0.42, 3.02 ]
Total (95% CI) 189 187 100.0 % 0.92 [ 0.37, 2.26 ]
Total events: 9 (Combined therapy), 10 (Epinephrine alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Combination therapy Epineprhine alone
A D D I T I O N A L T A B L E S
Table 1. Procedure-related adverse effects
Study ID Adverse effects in epinephrine plus second agent
group (combined therapy)
Adverse effects in epinephrine group
Lo 2006 None None
Chung 1993 Quote, page 613: “A 75-year-old man in the
epinephrine plus STD group had abdominal pain after
injection therapy. An actively bleeding pre-pyloric ulcer
had been injected with 8 ml of epinephrine followed
by 1 ml of STD. Signs of upper abdominal peritonitis
developed 36 hours later. At operation extensive infarc-
tion and necrosis were seen along the lesser curvature
of the stomach. The right gastric artery was cord-like
and thrombosed along its course. Extensive coagulative
necrosis was observed in the arteries in the muscularis
propria. It is likely that the STD was injected directly
into the right gastric artery and travelled in the artery
along the lesser curvature. It caused coagulative necrosis
in the smaller arteries and necrosis along the lesser cur-
No untoward cardiovascular events were observed dur-
ing endoscopic injection therapy in either group
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Table 1. Procedure-related adverse effects (Continued)
vature of the stomach. Fortunately, the patient made an
uneventful recovery after a subtotal gastrectomy”
Chung 1997 Two participants underwent surgery for perforations re-
lated to heat probe application
None
Chung 1999 No ’notable’ complications were reported in the haemo-
clip and combined therapy groups
Three participants.
In 1 case, bleeding was aggravated during
treatment of a non-bleeding visible vessel, and surgical
intervention for control of bleeding ultimately was re-
quired. In the other 2 cases, submucosal haematoma de-
veloped
Grgov 2012 None None
Kubba 1996 None None
Lin 1993 None None
Lin 1999 None None
Loizou 1991 None Text states no procedure-related complications, but in
1 participant in the epinephrine group, injection pro-
voked spurting haemorrhage
Pescatore 2002 Perforation (leading to surgical intervention) (n = 1)
Non-procedure-related complications: pneumonia (n =
1)
Ulcer haemorrhage (n = 1 patient in group E) induced
by epinephrine injection that led to surgical intervention
Non-procedure-related complications were reported:
pneumonia (n = 3); stroke (n = 1)
Sollano 1991 Mucosal injury or necrosis (n = 1) Mucosal injury or necrosis (n = 1)
Villanueva 1993 Size of ulcer increased 5-fold after infection, developed
pneumoperitoneum, resolved spontaneously
None
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A P P E N D I C E S
Appendix 1. MEDLINE search
OvidMEDLINE(R) 1946 toMayWeek 2 2014, OvidMEDLINE(R) Daily UpdateMay 22, 2014, OvidMEDLINE(R) In-Process
& Other Non-Indexed Citations May 22, 2014
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp peptic ulcer/
13. exp peptic ulcer hemorrhage/
14. exp peptic ulcer perforation/
15. exp duodenal ulcer/
16. exp stomach ulcer/
17. (pep$ adj5 ulcer$).tw.
18. (stomach adj5 ulcer$).tw.
19. (duoden$ adj5 ulcer$).tw.
20. (gastr$ adj5 ulcer$).tw.
21. (bleed$ adj5 ulcer$).tw.
22. (rebleed$ adj5 ulcer$).tw.
23. (recurrent adj5 bleed$ adj5 ulcer$).tw.
24. (acute adj5 bleed$ adj5 ulcer$).tw.
25. exp gastrointestinal hemorrhage/
26. (gastrointestinal adj5 bleed$).tw.
27. (gastrointestinal adj5 rebleed$).tw.
28. (gastrointestinal adj5 hemorrhag$).tw.
29. (gastrointestinal adj5 haemorrhag$).tw.
30. (ulcer adj5 hemorrhag$).tw.
31. (ulcer adj5 haemorrhag$).tw.
32. (mucos$ adj5 injur$).tw.
33. (mucos$ adj5 ero$).tw.
34. (gastr$ adj5 ero$).tw.
35. (stomach adj5 ero$).tw.
36. or/12-35
37. exp epinephrine/
38. epinephrine.tw.
39. exp vasoconstrictor agents/
40. or/37-39
41. (argon adj5 plasma adj5 coagulat$).tw.
42. exp sclerotherapy/
43. sclerotherap$.tw.
44. exp electrocoagulation/
45. exp hemostasis/
46. exp hemostasis, endoscopic/
47. exp lasers/
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48. exp endoscopy gastrointestinal/
49. electrocoagulat$.tw.
50. (therm$ adj5 coagulat$).tw.
51. (heater adj5 probe).tw.
52. laser$.tw.
53. endoclip$.tw.
54. hemoclip$.tw.
55. (monopolar adj5 coagulat$).tw.
56. (multipolar adj5 coagulat$).tw.
57. (bipolar adj5 coagulat$).tw.
58. exp sclerosing solutions/
59. sclerosant$.tw.
60. polidocanol.tw.
61. exp polyethylene glycols/
62. (endoscopic adj3 inject$).tw.
63. thrombin.tw.
64. fibrin glue.tw.
65. exp fibrin tissue adhesive/
66. cyanoacrylate.tw.
67. exp enbucrilate/
68. or/41-67
69. 36 and 40 and 68
70. 11 and 69
71. limit 70 to ed=20090601-20140523
Appendix 2. CENTRAL search strategy
EBM Reviews-Cochrane Central Register of Controlled Trials April 2014
1. exp peptic ulcer/
2. exp peptic ulcer hemorrhage/
3. exp peptic ulcer perforation/
4. exp duodenal ulcer/
5. exp stomach ulcer/
6. (pep$ adj5 ulcer$).tw.
7. (stomach adj5 ulcer$).tw.
8. (duoden$ adj5 ulcer$).tw.
9. (gastr$ adj5 ulcer$).tw.
10. (bleed$ adj5 ulcer$).tw.
11. (rebleed$ adj5 ulcer$).tw.
12. (recurrent adj5 bleed$ adj5 ulcer$).tw.
13. (acute adj5 bleed$ adj5 ulcer$).tw.
14. exp gastrointestinal hemorrhage/
15. (gastrointestinal adj5 bleed$).tw.
16. (gastrointestinal adj5 rebleed$).tw.
17. (gastrointestinal adj5 hemorrhag$).tw.
18. (gastrointestinal adj5 haemorrhag$).tw.
19. (ulcer adj5 hemorrhag$).tw.
20. (ulcer adj5 haemorrhag$).tw.
21. (mucos$ adj5 injur$).tw.
22. (mucos$ adj5 ero$).tw.
23. (gastr$ adj5 ero$).tw.
24. (stomach adj5 ero$).tw.
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25. or/1-24
26. exp epinephrine/
27. epinephrine.tw.
28. exp vasoconstrictor agents/
29. or/26-28
30. (argon adj5 plasma adj5 coagulat$).tw.
31. exp sclerotherapy/
32. sclerotherap$.tw.
33. exp electrocoagulation/
34. exp hemostasis/
35. exp hemostasis, endoscopic/
36. exp lasers/
37. exp endoscopy gastrointestinal/
38. electrocoagulat$.tw.
39. (therm$ adj5 coagulat$).tw.
40. (heater adj5 probe).tw.
41. laser$.tw.
42. endoclip$.tw.
43. hemoclip$.tw.
44. (monopolar adj5 coagulat$).tw.
45. (multipolar adj5 coagulat$).tw.
46. (bipolar adj5 coagulat$).tw.
47. exp sclerosing solutions/
48. sclerosant$.tw.
49. polidocanol.tw.
50. exp polyethylene glycols/
51. (endoscopic adj3 inject$).tw.
52. thrombin.tw.
53. fibrin glue.tw.
54. exp fibrin tissue adhesive/
55. cyanoacrylate.tw.
56. exp enbucrilate/
57. or/30-56
58. 25 and 29 and 57
59. limit 58 to yr=2009-2014
Appendix 3. EMBASE search strategy
EMBASE 1980 to Week 20 2014
1. random:.tw. or placebo:.mp. or double-blind:.tw.
2. exp peptic ulcer/
3. exp peptic ulcer hemorrhage/
4. exp peptic ulcer perforation/
5. exp duodenal ulcer/
6. exp stomach ulcer/
7. (pep$ adj5 ulcer$).tw.
8. (stomach adj5 ulcer$).tw.
9. (duoden$ adj5 ulcer$).tw.
10. (gastr$ adj5 ulcer$).tw.
11. (bleed$ adj5 ulcer$).tw.
12. (rebleed$ adj5 ulcer$).tw.
13. (recurrent adj5 bleed$ adj5 ulcer$).tw.
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14. (acute adj5 bleed$ adj5 ulcer$).tw.
15. exp gastrointestinal hemorrhage/
16. (gastrointestinal adj5 bleed$).tw.
17. (gastrointestinal adj5 rebleed$).tw.
18. (gastrointestinal adj5 hemorrhag$).tw.
19. (gastrointestinal adj5 haemorrhag$).tw.
20. (ulcer adj5 hemorrhag$).tw.
21. (ulcer adj5 haemorrhag$).tw.
22. (mucos$ adj5 injur$).tw.
23. (mucos$ adj5 ero$).tw.
24. (gastr$ adj5 ero$).tw.
25. (stomach adj5 ero$).tw.
26. or/2-25
27. exp epinephrine/
28. epinephrine.tw.
29. exp vasoconstrictor agents/
30. or/27-29
31. (argon adj5 plasma adj5 coagulat$).tw.
32. exp sclerotherapy/
33. sclerotherap$.tw.
34. exp electrocoagulation/
35. exp hemostasis/
36. exp hemostasis, endoscopic/
37. exp lasers/
38. exp endoscopy gastrointestinal/
39. electrocoagulat$.tw.
40. (therm$ adj5 coagulat$).tw.
41. (heater adj5 probe).tw.
42. laser$.tw.
43. endoclip$.tw.
44. hemoclip$.tw.
45. (monopolar adj5 coagulat$).tw.
46. (multipolar adj5 coagulat$).tw.
47. (bipolar adj5 coagulat$).tw.
48. exp sclerosing solutions/
49. sclerosant$.tw.
50. polidocanol.tw.
51. exp polyethylene glycols/
52. (endoscopic adj3 inject$).tw.
53. thrombin.tw.
54. fibrin glue.tw.
55. exp fibrin tissue adhesive/
56. cyanoacrylate.tw.
57. exp enbucrilate/
58. or/31-57
59. 26 and 30 and 58
60. 1 and 59
61. limit 60 to em=200901-201420
76Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
WH A T ’ S N E W
Last assessed as up-to-date: 4 July 2014.
Date Event Description
30 May 2014 New search has been performed Updated with new search results, 1 new trial added
30 May 2014 New citation required and conclusions have changed New author (CB); new, updated results
H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 2, 2007
Date Event Description
5 November 2009 New search has been performed Updated.
16 June 2008 Amended Converted to new review format.
17 January 2007 New citation required and conclusions have changed Substantive amendment
6 January 2007 Amended Minor update.
14 February 2006 Amended New studies found and included or excluded.
C O N T R I B U T I O N S O F A U T H O R S
Mercedes Vergara and Xavier Calvet developed the protocol, performed the main search strategy, assessed eligibility, extracted data,
performed statistical analyses (meta-analysis) and wrote the manuscript.
Javier P. Gisbert was involved in reviewing the final manuscript and providing relevant methodological support.
Cathy Bennett updated the review in May 2014, along with Mercedes Vergara.
Mercedes Vergara is responsible for data accuracy and is the guarantor of this review.
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D E C L A R A T I O N S O F I N T E R E S T
Dr Cathy Bennett is the proprietor of Systematic Research Ltd, a company that provides research services and is an employee of that
company; Dr Bennett received a consultancy fee, as well as travel expenses for travel to work-related meetings and conferences. Dr
Bennett has received consultancy fees for other Cochrane reviews and for her work in evidence-based medicine. Dr Bennett is a member
of the data monitoring committee for the BOSS clinical trial; this work is not related to writing of systematic reviews.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Mercedes Vergara, Xavier Calvet and Javier P Gisbert are investigators of the Centro de Investigación en Red de Enfermedades
Hepáticas y Digestivas (CIBERhed). CIBERhed is funded by the Instituto de Salud Carlos III., Spain.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We edited the background text of this review protocol after initial publication by providing updated information.
For studies with more than one active intervention and only one control group, we selected the intervention that most closely matched
our inclusion criteria and excluded the others (see Higgins 2011, Chapter 16.5.4).
We completely updated and revised the methods section for clarity, although our methods remain unchanged from the previous version
of the review.
We checked all data extracted and amended minor errors.
We updated the tables, content and presentation of the review to be consistent with MECIR reporting standards for systematic reviews.
This included the addition of domains to the risk of bias tables and a PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) flow chart of studies.
We clarified that persistent bleeding is failure of initial haemostasis, and recurrent bleeding is bleeding that recurs after initial haemostasis.
Rebleeding rates included both endoscopic and clinical rebleeding.
N O T E S
None.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Combined Modality Therapy [methods]; Epinephrine [∗administration & dosage]; Hemostasis, Endoscopic [∗methods]; Peptic Ulcer
Hemorrhage [mortality; prevention & control; ∗therapy]; Randomized Controlled Trials as Topic; Secondary Prevention [methods];
Vasoconstrictor Agents [∗administration & dosage]
MeSH check words
Adult; Humans
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